atorvastatin has been researched along with Inflammation in 282 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (0.71) | 18.2507 |
| 2000's | 92 (32.62) | 29.6817 |
| 2010's | 139 (49.29) | 24.3611 |
| 2020's | 49 (17.38) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmad Nazri, KA; Buang, F; Haji Mohd Saad, Q; Jantan, I; Jubri, Z; Mohd Fauzi, N | 1 |
| Gao, C; Gong, Z; Huang, J; Jiang, R; Jiang, W; Li, X; Liu, X; Nie, M; Quan, W; Tian, Y; Wang, D; Xiang, T; Yuan, H; Yuan, J; Zhan, D; Zhang, J | 1 |
| Li, N; Qiang, S; Wang, D; Yang, L; Zhao, Z | 1 |
| Fan, Y; Gao, C; Huang, J; Jiang, R; Liu, X; Ma, J; Wang, D; Wei, H; Yang, G; Zhang, J; Zhao, Z | 1 |
| Cowen, PJ; De Giorgi, R; Harmer, CJ; Martens, M; Rizzo Pesci, N | 1 |
| Chen, C; Chen, D; Guan, J; Liu, S; Sui, L; Sun, X | 1 |
| Abtahi Froushani, SM; Etemadi, S; Hashemi Asl, SM; Mahmoudian, A | 1 |
| Huang, J; Kang, H; Li, M; Liu, J; Turhon, M; Wang, K; Yang, X; Zhang, Y | 1 |
| Coskun, G; Efendic, F; Erdem, E; Hayretdag, C; Irkorucu, O; Keles, P; Kuras, S; Pence, HH; Polat, S; Saker, D; Sapmaz, E; Sapmaz, T; Sevgin, K; Tekayev, M; Topkaraoglu, S | 1 |
| Fan, Y; Gao, C; Huang, J; Jiang, R; Wang, D; Wang, Z; Yang, L; Zhang, J; Zhao, Z | 1 |
| Kowalcze, K; Krysiak, R; Okopień, B | 1 |
| Burns, JC; He, M; Hoffman, HM; Kim, J; Shimizu, C; Shyy, JY; Tremoulet, AH | 1 |
| Alaylioglu, M; Dogan, AS; Dursun, E; Gezen-Ak, D; Onal, B; Ugurlucan, M; Yenmis, G | 1 |
| Al Gharram, T; Mayyas, F | 1 |
| Blom, AB; Kruisbergen, NNL; Pieterman, EJ; Princen, HMG; van den Bosch, MHJ; van der Kraan, PM; van Gemert, Y; van Lent, PLEM | 1 |
| Bellandi, F; Biagini, F; Comeglio, M; Leoncini, M; Magnaghi, G; Maioli, M; Martini, O; Toso, A; Villani, S | 1 |
| Elakkad, YE; Elgendy, HA; Ismail, RM; Makky, AMA; Younes, NF | 1 |
| Deng, Y; Dong, L; He, Y; Li, F; Tang, Y; Tao, Z; Wen, S | 1 |
| Cho, HC; Choi, SH; Golfetto Miskiewicz, IC; Lee, J; Lee, JI; Lee, Y; Lee, YK | 1 |
| Campos-Estrada, C; Denegri, M; González-Herrera, F; Kemmerling, U; Maya, JD; Urarte, E; Villalón, L | 1 |
| Anfossi, R; Carrillo, I; Castillo, C; Catalán, M; Clayton, NS; González-Herrera, F; Guzmán-Rivera, D; Kemmerling, U; Maya, JD; Olea-Azar, C; Quilaqueo, ME; Quintero-Pertuz, H; Ridley, AJ; Rivera-Meza, M; Vivar, R | 1 |
| Caspers, MPM; Giera, M; Inia, JA; Jukema, JW; Menke, AL; Morrison, MC; Pieterman, EJ; Princen, HMG; Stokman, G; van den Hoek, AM; Verschuren, L | 1 |
| Baker, JV; Gorelick, RJ; Krishnan, S; Laidlaw, E; Lisco, A; Manion, M; Migueles, SA; Mystakelis, HA; Poole, A; Rupert, A; Sereti, I; Welker, JL; Wilson, E | 1 |
| Deng, J; He, Y; Huang, L; Li, Y; Wang, S | 1 |
| Adeneye, AA; Afolabi, SO; Ajayi, AM; Folahan, JT; Njan, AA; Okoye, II; Olorundare, OE; Oyewopo, AO; Soyemi, SS | 1 |
| Li, MR; Li, NS; Lu, LQ; Luo, XJ; Peng, J; Peng, JY; Tang, LJ | 1 |
| Hu, M; Peng, X; Pu, X; Shi, S; Yu, X | 1 |
| An, N; Chen, L; Chen, Z; Feng, L; Huang, Z; Li, Q; Wang, R; Wu, W; Yan, Y; Yang, X; Zhang, W; Zhong, M; Zhu, Y | 1 |
| Huang, H; Lu, C; Luo, T; Wu, Q; Xiong, S; Xiong, Y; Zeng, J; Zhang, Z | 1 |
| Abdelnoor, AM; Al-Khoury, DK; Hussein, HM; Rahal, EA | 1 |
| Liu, Z; Zeng, H | 1 |
| Cong-Rong, T; Fan, Y; Hai-Na, Z; Jing, L; Lei-Mei, X; Ruo-Lan, S; Xu-Ben, Y; Yan-Cheng, C; Ye-Xuan, W | 1 |
| Chatsudthipong, V; Cherngwelling, R; Jaikumkao, K; Lungkaphin, A; Pengrattanachot, N; Pongchaidecha, A; Swe, MT; Thongnak, L | 1 |
| Cui, J; Grau, MS; Jaffer, FA; Jhajj, HS; Kessinger, CW; Libby, P; McCarthy, JR; Misra, S | 1 |
| Arafa, MG; El-Dahan, MS; Girgis, GNS | 1 |
| Bar-Klein, G; Friedman, A; Hameed, MQ; Jozwiak, S; Kaminski, RM; Klein, P; Klitgaard, H; Koepp, M; Löscher, W; Prince, DA; Rotenberg, A; Twyman, R; Vezzani, A; Wong, M | 1 |
| Atasoy, Ö; Erbaş, O; Solmaz, V | 1 |
| Agnew, D; Arora, R; Hossaini Nasr, S; Huang, X; Kauffman, N; Parameswaran, N; Qian, C; Ramadan, S; Rashidijahanabad, Z; Zinn, KR | 1 |
| Fu, G; Li, Y; Luan, Y; Lv, Q; Xu, T; Zhang, W; Zhao, L | 1 |
| Devasani, K; Kaul, R; Majumdar, A | 1 |
| Dong, S; Feng, Y; Jiang, Q; Li, J; Li, S; Li, T; Lin, W; Liu, B; Luo, H; Ou, Z; Qi, Q; Xu, Q; Yu, Z; Zeng, X; Zha, L; Zhang, M; Zhao, L | 1 |
| Blanco, J; Bonjoch, A; Clotet, B; Echeverría, P; Jiménez, M; Loste, C; Negredo, E; Pérez-Álvarez, N; Puig, J; Urrea, V | 1 |
| Aslan, G; İlhan, N; Sahin, K; Sahna, E; Sezgin, D; Tuzcu, M | 1 |
| Feng, B; Li, Z; Yang, P | 1 |
| Aref'eva, TI; Filatova, AY; Radyukhina, NV; Ruleva, NY; Zubkova, ES | 1 |
| Aguilar, GS; Chai, Z; Lakshman, S; Lamon-Fava, S; Lichtenstein, AH; Matthan, NR; Turner, JR; Urban, JF; Walker, ME; Ye, S | 1 |
| Hüttl, M; Kazdová, L; Malínská, H; Marková, I; Miklánková, D; Oliyarnyk, O; Poruba, M; Rácová, Z; Večeřa, R | 1 |
| Hoogeveen, RM; Kaiser, Y; Kroon, J; Moens, SJB; Stroes, ESG; Verberne, HJ; Verweij, SL; Vogt, L | 1 |
| Jiaqiong, L; Ming, L; Xiaoyong, L; Xinxue, L; Xuexian, T; Yan, L; Yinglan, L; Yue, G; Zena, H | 1 |
| Choi, KC; Hong, DK; Kang, BS; Kho, AR; Park, KH; Park, WJ; Suh, SW | 1 |
| Gao, Y; Liu, C; Yu, Y; Zhu, C | 1 |
| Hellberg, S; Jauhiainen, M; Knuuti, J; Liljenbäck, H; Metso, J; Nuutila, P; Roivainen, A; Saraste, A; Saukko, P; Savisto, N; Silvola, JMU; Sippola, S; Ståhle, M; Virta, J; Ylä-Herttuala, S | 1 |
| Colas, RA; Dalli, J; Souza, PR; Walker, ME | 1 |
| Chang, TY; Chen, Z; Chien, S; Huang, TS; Li, YS; Nguyen, P; Quon, S; Shyy, J; Subramaniam, S; Wang, KC | 1 |
| Al-Moujahed, A; Bouzika, P; Hu, Y; Lin, H; Miller, JW; Notomi, S; Tian, B; Tsoka, P; Vavvas, DG | 1 |
| Anoopkumar-Dukie, S; Davey, AK; McFarland, AJ | 1 |
| Chen, L; Huang, X; Li, R | 1 |
| Lv, YZ; Wang, HM; Wang, ZZ; Xiao, W; Zhou, JM | 1 |
| Cannon, CP; Guo, J; Khan, N; Steen, DL; Umez-Eronini, AA | 1 |
| Fernando, T; Kang, Q; Li, X; Wan, Z; Yang, M | 1 |
| Baydoun, D; Ibdah, R; Ibrahim, K; Mayyas, F | 1 |
| Wang, H; Wang, X; Yang, S; Zhang, J | 1 |
| Christenson, R; deFilippi, C; Fitch, KV; Grinspoon, SK; Hoffmann, U; Joyce, J; Lo, J; Looby, SE; Lu, MT; Park, EA; Wu, A | 1 |
| Ahmed, YM; Baothman, OAS; Kaleemuddin, M; Khan, I; Khan, TJ; Kuerban, A; Mehanna, MG; Siddiqui, AM; Yasir, M; Zamzami, MA | 1 |
| Guo, Y; Wang, H; Yin, J | 1 |
| Barroso, MV; Cattani-Cavalieri, I; Gitirana, LB; Lanzetti, M; Melo, AC; Quesnot, N; Valença, SS | 1 |
| Beshah, E; Goldbaum, A; Jang, S; Lakshman, S; Lamon-Fava, S; Lichtenstein, AH; Matthan, NR; Meng, H; Molokin, A; Solano-Aguilar, G; Stanley, J; Urban, JF; Walker, ME; Xie, Y | 1 |
| Dammers, R; den Hertog, HM; Dirven, CMF; Holl, DC; Jellema, K; Kho, KH; Lingsma, HF; Miah, IP; Peul, WC; van der Gaag, NA; van Kooten, F; Volovici, V | 1 |
| Ahmed, LA; Attalla, DM; Khattab, MM; Zaki, HF | 1 |
| Chu, Y; Ding, M; Ma, H; Ren, H; Wang, C; Xu, Q; Yao, Q; Zuo, G | 1 |
| Castañeda-Espinoza, R; Cervantes-Cardona, GA; Cervantes-Guevara, G; Contreras-Hernández, GI; Fuentes-Orozco, C; Gálvez-Gastelum, FJ; García-Martinez, D; Garcia-Salazar, SJ; Gómez-Navarro, B; González-Espinoza, E; González-Ojeda, A; Pérez-Landeros, JE; Ramírez-Robles, JN; Yáñez-Sánchez, I; Zepeda-González, A | 1 |
| Baumgartner, J; Ebenbauer, B; Fischer, MB; Hohensinner, PJ; Huber, K; Speidl, WS; Thaler, B; Wojta, J | 1 |
| Andersen, LW; Chase, M; Cocchi, MN; Donnino, MW; Holmberg, MJ; Liu, X | 1 |
| Pan, H; Rui, R; Sun, B; Wang, X; Zhang, L | 1 |
| Baldascino, F; Cabaro, S; Caruso, A; D'Esposito, V; Davin, L; De Bellis, A; Ferrara, N; Ferro, A; Formisano, P; Formisano, R; Grimaldi, MG; Lancellotti, P; Leosco, D; Paolillo, S; Parisi, V; Perrone Filardi, P; Petraglia, L; Rengo, G; Vitale, D | 1 |
| Allan, SM; Badrock, AP; Barrington, J; Crilly, S; Fotiou, E; Hudson, G; Hurlstone, A; Kasher, PR; Laurie, SE; Njegic, A; Parry-Jones, AR; Rivers-Auty, J; Webb, K; Young, HL | 1 |
| Guo, J; Li, T; Liu, Y; Yao, Y; Zeng, Z; Zhang, R; Zhao, Y | 1 |
| Guo, X; Li, X; Wang, L; Wang, P; Xia, X | 1 |
| Boonyapakorn, C; Chattipakorn, N; Patchanee, P; Pongkan, W; Thassakorn, P | 1 |
| Chen, B; Chen, X; Cheng, D; Li, X; Lin, C; Sun, W; Wang, J; Wu, T; Xiao, H | 1 |
| Huang, D; Liu, H; Niu, T; Wang, K; Yang, J | 1 |
| De Servi, S; Leoncini, M; Toso, A | 1 |
| Badran, B; El-Achkar, GA; Habib, A; Hamade, E; Jaffa, AA; Motterlini, R; Mouawad, CA; Mrad, MF | 1 |
| Ahmed, T; Ahsan, CR; Al Shoyaib, A; Archie, SR; Chowdhury, FA; Faruk, A | 1 |
| Goldbaum, A; Jang, S; Lakshman, S; Lamon-Fava, S; Lichtenstein, AH; Matthan, NR; Meng, H; Molokin, A; Solano-Aguilar, G; Urban, JF; Walker, ME | 1 |
| Alvi, SS; Ansari, IA; Khan, MS; Li, M; Li, Y; Liu, Z; Wang, G | 1 |
| Jing, LM; Li, H; Liu, HL; Luo, JP; Shen, ZQ; Yang, SL; Yang, Y | 1 |
| Aguirre, AC; Amaral, JB; Barbosa, SP; Bianco, HT; Fonseca, FA; França, CN; Izar, MC; Lins, LC; Matos, LN; Santana, JM | 1 |
| Banach, M; Bielecka-Dabrowa, A; Mikhailidis, DP; Rizzo, M; Rysz, J; von Haehling, S | 1 |
| Das, DK; Das, N; Dey, S; Kesh, SB; Khan, A; Manna, K; Sikder, K | 1 |
| Ballet, S; Bini, J; Corot, C; Dickson, SD; Fayad, ZA; Izquierdo-Garcia, D; Klink, A; Lancelot, E; Mateo de Castro, J; Millon, A; Robert, P | 1 |
| Brodowski, K; Jaworski, K; Kosior, DA; Krzykwa, A; Opolski, G; Zylińska, E | 1 |
| Abdelbaky, A; Alon, A; Beals, CR; Dansky, H; Farkouh, ME; Fayad, ZA; Klimas, MT; Mogg, R; Nunes, IO; Rudd, JH; Shankar, SS; Subramanian, SS; Tawakol, A | 1 |
| Gerber, BL | 1 |
| Dong, QT; Gao, RL; Geng, YJ; Gersh, BJ; He, ZX; Lu, MJ; Qian, HY; Qiao, SB; Shen, R; Song, L; Yang, YJ; Zhao, SH | 1 |
| Gitirana, LB; Machado, MN; Magalhães, CB; Melo, AC; Porto, LC; Ribeiro, ML; Santos, JC; Valença, SS; Zin, WA | 1 |
| Cieśla-Dul, M; Potaczek, DP; Undas, A; Żółciński, M | 1 |
| Lappegård, KT; Pop, G; Pop-Purceleanu, M; Sexton, J; Tendolkar, I; van Heerde, W | 1 |
| Medvedeva, EA; Seleznev, EI; Shchukin, IuV | 1 |
| Chahal, N; Manlhiot, C; McCrindle, BW; Niedra, E; Yeung, RS | 1 |
| Do e, Z; Fukumoto, Y; Kanazawa, M; Matsumoto, Y; Sato, A; Satoh, K; Shimizu, T; Shimokawa, H; Takahashi, K | 1 |
| Briolant, S; Desgrouas, C; Dormoi, J; Pascual, A; Pradines, B; Travaillé, C | 1 |
| Alon, A; Emami, H; Farkouh, M; Fayad, ZA; Fifer, KM; Rudd, JHF; Shankar, SS; Singh, P; Subramanian, S; Tawakol, A; Van Dyke, TE; Vijayakumar, J; Vucic, E | 1 |
| Tremoulet, AH | 2 |
| Manlhiot, C; McCrindle, BW | 1 |
| Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP | 1 |
| Alves, Mdo S; de Araújo Júnior, RF; de Araújo, AA; de Moura, LM; de Souza, LB; Rocha, HO; Souza, TO; Torres, KP | 1 |
| Chen, Y; Huang, A; Ku, H; Li, LC; Li, Q; Moorhead, JF; Powis, SH; Ruan, XZ; Varghese, Z; Wheeler, DC; Zhao, L | 1 |
| Abdallah, FR; Aldohmy, S; Elseweidy, MM; Kassem, HM; Younis, NN | 1 |
| He, GX; Liu, XL; Xu, HP; Zhao, XJ | 1 |
| Chen, J; Cui, W; Jiang, R; Li, T; Quan, W; Tian, Y; Wang, D; Wang, Y; Yu, H; Zhang, J; Zhou, L | 1 |
| Anticoli, S; Gambardella, L; Malorni, W; Maselli, A; Matarrese, P; Panusa, A; Ruggieri, A; Vona, R | 1 |
| Azushima, K; Dejima, T; Kanaoka, T; Kobayashi, R; Maeda, A; Ohsawa, M; Tamura, K; Toya, Y; Umemura, S; Uneda, K; Wakui, H | 1 |
| Cai, J; Ding, X; Fang, Y; Liu, S; Liu, T; Yu, X; Zhang, B; Zhang, H | 1 |
| Chen, Y; Li, Q; Moorhead, JF; Powis, SH; Ruan, XZ; Varghese, Z; Wheeler, DC; Zhao, L | 1 |
| Caporale, R; Clemente, AM; Filippelli, A; Gelli, AM; Guasti, D; Musilli, C; Paccosi, S; Parenti, A; Romagnoli, P; Torcia, MG | 1 |
| Chen, Y; Chen, Z; Gu, M; Lin, Y; Luo, N; Wang, J; Wang, X | 1 |
| Ahmadi, M; Bacot, S; Barone-Rochette, G; Broisat, A; Devoogdt, N; Dumas, LS; Fagret, D; Ghezzi, C; Lahoutte, T; Perret, P; Riou, LM; Slimani, L; Soubies, A; Toczek, J | 1 |
| Boiati, RF; dos Santos Batista, JG; Jacobsen, O; Manchini, MT; Nascimento, JW; Silva Júnior, JA | 1 |
| Dostal, E; Gaspar, L; Goliasch, G; Hofbauer, SL; Huber, K; Kastl, SP; Katsaros, KM; Krychtiuk, KA; Maurer, G; Oravec, S; Pfaffenberger, S; Pongratz, T; Speidl, WS; Wojta, J; Wonnerth, A | 1 |
| Bespalova, ID; Kaliuzhin, VV; Mediantsev, IuA; Murashev, BIu; Osikhov, IA; Riazantseva, NV | 1 |
| Guan, Y; Guo, HY; Shan, ZL; Wang, YT; Yuan, HT; Zhang, Y | 1 |
| Abd Elmaaboud, MA; Albarraq, AA; Kabel, AM | 1 |
| Cheng, Y; Guo, A; Liu, C; Liu, X; Liu, Y; Shi, H; Yang, J; Zhang, L | 1 |
| Abdelbaky, A; Ballantyne, CM; Du, S; Ehlgen, A; Emami, H; Farkouh, ME; Farmer, M; Fayad, ZA; Hayes, W; Kim, J; Langenickel, TH; Li, L; Mohler, ER; Roth, E; Subramanian, S; Tawakol, A; Velasquez, L; Vucic, E | 1 |
| Akalin Çiftçi, G; Akalin, A; Alataş, İÖ; Ertorun, İ; Musmul, A | 1 |
| Atarashi, H; Kohashi, K; Kosugi, M; Kusama, Y; Nakagomi, A; Shibui, T; Shimizu, W | 1 |
| Callies, S; Demmer, P; Hu, N; Janssen, H; Larmann, J; Loghmani-khouzani, H; Schuett, H; Sölter, G; Theilmeier, G; Tietge, UJ; Wagner, CS; Warnecke, G | 1 |
| Bai, L; Chen, Y; Fan, J; Gao, S; Guan, H; Li, Y; Lin, Y; Liu, E; Sun, L; Wang, Y; Zhao, S; Zhu, N | 1 |
| Berns, SA; Bondareva, IN; Smakotina, SA; Zelendinova, AR | 1 |
| Lee, CR; Zeldin, DC | 1 |
| Chen, LZ; Huang, XS; Li, R; Zhao, SP | 1 |
| Arnao, V; Corpora, F; Della Corte, V; Di Bona, D; Di Raimondo, D; Iacopino, DG; Maida, C; Maugeri, R; Pecoraro, R; Pinto, A; Simonetta, I; Tuttolomondo, A | 1 |
| Brugia, M; Capestro, F; Crescenzi, G; D'Alfonso, A; Pierri, MD; Scocco, V; Torracca, L; Zingaro, C | 1 |
| Gjorstrup, P; Kleemann, R; Kooistra, T; Morrison, MC; Salic, K; Verschuren, L; Wielinga, PY; Wu, L | 1 |
| Chen, ZC; Cheng, KL; Cheng, SY; Guo, YZ; Ou, MD; Wang, Q; Xue, JJ; Zeng, WJ; Zhang, YT | 1 |
| Chen, F; Chen, H; Cui, W; Jin, Y; Liu, D; Liu, F; Lu, J | 1 |
| Chen, Y; Li, B; Moorhead, JF; Ruan, XZ; Varghese, Z; Wu, W; Yang, P; Zhao, L; Zhou, W | 1 |
| Khodagholi, F; Mehrpour, M; Naderi, N; Nasoohi, S; Simani, L | 1 |
| Hua, BJ; Li, HY; Liu, ZQ; Su, YY; Zhang, YF | 1 |
| Asadikaram, G; Ebrahimi, N; Kazemi Arababadi, M; Kiani, Z; Kohan, F; Masoumi, M; Nasiri, AA; Sepehri, Z; Sheikh Fathollahi, M | 1 |
| Guo, Y; Liu, Q; Peng, R; Xu, D; Zhao, S; Zhao, W; Zhao, Y | 1 |
| Lee, JK; Singh, AK; Singh, I; Won, JS | 1 |
| Chandra, N; Mateen, AA; Naidu, MU; Raju, YS; Usharani, P | 1 |
| Devaraj, S; Jialal, I; Siegel, D; Singh, U | 1 |
| Drechsler, C; Krane, V; Lilienthal, J; März, W; Wanner, C; Winkler, K | 2 |
| Blanco-Colio, LM; de Teresa, E; Egido, J; Farsang, C; Gaw, A; Gensini, G; Langer, A; Leiter, LA; Martín-Ventura, JL; Martineau, P | 2 |
| Hoeger, KM | 1 |
| Amato, M; Arquati, M; Baldassarre, D; Brusoni, B; Camera, M; Cortellaro, M; Fiorentini, C; Montorsi, P; Porta, B; Romano, S; Tremoli, E; Veglia, F | 1 |
| Chen, Y; Cheng, X; Ding, Y; Liao, M; Liao, YH; Tang, T; Wang, M; Xia, C; Xie, J; Yao, R; Yu, X | 1 |
| Barderas, MG; Dardé, VM; De la Cuesta, F; Egido, J; Jiménez-Nácher, JJ; López-Bescós, L; Tarín, N; Tuñón, J; Vivanco, F | 1 |
| Amano, A; Daida, H; Kajimoto, K; Kasai, T; Kojima, Y; Miyauchi, K; Niinami, H; Shimada, A; Shimada, K | 1 |
| Briley-Saebo, KC; Fayad, ZA; Mani, V; Razzouk, L | 1 |
| Boyle, JR; Brown, AP; Gaunt, ME; Gillard, JH; Graves, MJ; Hayes, PD; Howarth, SP; Kirkpatrick, PJ; Li, ZY; Miller, SR; Patterson, AJ; Tang, TY; U-King-Im, JM; Varty, K; Walsh, SR; Warburton, EA; Zalewski, A | 1 |
| Fraley, AE; Ganz, P; Kinlay, S; Libby, P; Olsson, AG; Rifai, N; Schwartz, GG; Szarek, M; Tsimikas, S; Witztum, JL | 1 |
| Kitas, GD; Melas, N; Saratzis, A; Saratzis, N | 1 |
| Jin, R; Liu, M; Wang, F; Wang, Y | 1 |
| Chen, P; Gan, Y; Li, G; Wu, S; Xing, X; Zhang, J; Zhang, Y; Zhao, S | 1 |
| Aigbirhio, FI; Bird, JL; Davenport, AP; Davies, JR; Figg, N; Fryer, TD; Izquierdo-Garcia, D; Richards, HK; Rudd, JH; Warburton, EA; Weissberg, PL | 1 |
| Andrade, SP; Araújo, FA; Mendes, JB; Rocha, MA | 1 |
| Aikawa, E; Figueiredo, JL; Hembrador, S; Keliher, E; Kelly, K; Libby, P; Nahrendorf, M; Panizzi, P; Weissleder, R; Zhang, H | 1 |
| Frisbee, JC; Frisbee, SJ; Goodwill, AG; James, ME; Stapleton, PA | 1 |
| Kumar, VL; Wahane, VD | 1 |
| Adánez, G; Ayala, I; Castells, MT; Martín-Castillo, A; Pérez, BG; Polo, MT | 1 |
| Antoniades, C; Charakida, M; Kamboli, AM; Koniari, K; Marinou, K; Miliou, A; Nikolopoulou, A; Noutsou, M; Papageorgiou, N; Siasos, G; Stefanadi, E; Stefanadis, C; Tousoulis, D | 1 |
| Buchetti, B; Carnovale, A; Fallarino, M; Filetti, S; Gatti, A; Lenti, L; Lococo, E; Mandosi, E; Morano, S; Rossetti, M | 1 |
| Cengiz, SD; Dünder, I; Kaya, C; Pabuccu, R | 1 |
| Barber, MJ; Chasman, DI; Chatterjee, A; Hyde, CL; Krauss, RM; Li, X; Mangravite, LM; McCarty, CA; Nickerson, DA; Ridker, PM; Rieder, MJ; Rotter, JI; Smith, JD; Stephens, M; Wilke, RA; Williams, PT | 1 |
| Feng, L; Jiang, J; Li, M; Ren, H; Zhang, Y; Zhu, X | 1 |
| Cairns, R; Cannon, CP; Michael Gibson, C; Nazer, B; Ray, KK | 1 |
| Borggrefe, M; Dempfle, CE; Hoffmeister, HM; Lang, S; Suselbeck, T; Swoboda, S; Szabo, S; Walter, T | 1 |
| Joo, IW; Oh, HJ; Ryu, JH | 1 |
| Di Sciascio, G; Melfi, R; Nusca, A; Patti, G | 1 |
| Baer, A; Ky, B; Millar, JS; Pruscino, L; Rader, DJ; Wolfe, ML | 1 |
| Bergheanu, SC; Dallinga-Thie, GM; Hattori, H; Karalis, IK; Liem, AH; van Tol, A; Wolterbeek, R; Wouter Jukema, J | 1 |
| Bentz, K; Eick, C; Kettering, K; Laszlo, R; Menzel, KA; Schreieck, J; Schreiner, B | 1 |
| Sun, RP; Yang, L; Yin, P; Zhou, HY | 1 |
| Melfi, R; Nusca, A; Patti, G; Sciascio, GD | 1 |
| Harward, ML; Jones, MA; Joyce, CJ; Kostner, KM; Kruger, PS; Roberts, MS; Venkatesh, B | 1 |
| Haron, MM; Houssen, ME; Ibrahim, TM; Metwally, SS | 1 |
| El-Barbary, AM; Hamouda, HE; Hussein, MS; Ismail, RG; Rageh, EM; Wagih, AA | 1 |
| Demers, LM; Hogeman, CS; Kunselman, AR; Legro, RS; Raja-Khan, N; Stetter, CM | 1 |
| Cámara, C; Costo, A; Crespo, L; Fernández Pereira, L; Pereira, G; Sánchez Muñoz-Torrero, JF | 1 |
| Calisto, KL; Camacho, AC; Carvalheira, JB; Carvalho, Bde M; Guadagnini, D; Mittestainer, FC; Ropelle, ER; Saad, MJ | 1 |
| Chang, H; Jin, X; Qi, Z; Wang, Y; Zou, J | 1 |
| Abdel Rahman, MN; Abdelmotelb, AA | 1 |
| Bancells, C; Benítez, S; Ordóñez-Llanos, J; Pérez, A; Sánchez-Quesada, JL; Wägner, AM | 1 |
| Bi, H; Chen, WA; Daugherty, A; Hong, B; Luo, Y; Wang, JA; Wang, Y; Xie, X; Zhang, S | 1 |
| An, LM; Chang, WT; Chen, IJ; Lin, HL; Shen, KP; Wu, BN | 1 |
| He, B; Hu, LH; Jing, Q; Pu, J; Shao, Q; Shen, LH | 1 |
| Bash, D; Cavender, MA; Hislop, C; Kastelein, JJ; Nicholls, SJ; Rosenson, RS; Schwartz, G; Waters, DD | 1 |
| Saito, Y | 1 |
| Bao, W; Benessiano, J; Mallat, Z; Olsson, AG; Ryu, SK; Schwartz, GG; Tedgui, A; Tsimikas, S | 1 |
| Alberti, PF; Conti, V; Corazzi, T; Falcinelli, E; Gresele, P; Miglietta, D; Minuz, P; Momi, S; Monopoli, A; Ongini, E | 1 |
| Bryson, GL; Neilipovitz, DT; Taljaard, M | 1 |
| Chung, YT; Li, H; Liao, J; Yan, L; Yang, AL; Yang, GY; Zhang, M; Zhang, W | 1 |
| Claycombe, KJ; Nair, MG; Zhou, Z | 1 |
| Abe, K; Ikeda, Y; Kozuki, M; Kurata, T; Miyazaki, K; Morimoto, N; Ohta, Y | 1 |
| Li, W; Liu, K; Ma, A; Shao, L; Wang, J; Wang, Z; Wu, D; Zhang, P; Zhang, Y | 1 |
| Farah, R; Jubran, F; Khamisy-Farah, R | 1 |
| Deng, SB; Du, JL; Li, Q; She, Q; Xia, S | 1 |
| Cai, K; Hu, Y; Luo, Z; Xie, D | 1 |
| Berbée, JF; Havekes, LM; Hiemstra, PS; Khedoe, PP; Mol, IM; Princen, HM; Rensen, PC; Romijn, JA; Tsikas, D; van der Hoorn, JW; van Klinken, JB; Wang, Y; Wong, MC | 1 |
| Atkin, SL; Kilpatrick, ES; Sathyapalan, T; Shepherd, J | 1 |
| Arbustini, E; Camera, M; Cofrancesco, E; Cortellaro, M; Gabrielli, L; Negri, A; Rossi, F; Tremoli, E | 1 |
| Hamakubo, T; Itoh, T; Izumi, A; Kanke, T; Kodama, T; Mataki, C; Morikawa, S; Saito, Y; Takabe, W; Wada, Y | 1 |
| Alber, HF; Ares, MP; Dichtl, W; Dulak, J; Frick, M; Nilsson, J; Pachinger, O; Schwarzacher, SP; Weidinger, F | 1 |
| Aviles, RJ; Brennan, ML; Fu, X; Hazen, SL; Penn, MS; Shishehbor, MH; Sprecher, DL | 1 |
| Averkov, OV; Deev, AD; Gratsianskiĭ, NA; Pokrovskaia, EV; Vaulin, NA | 1 |
| Haloui, M; Jandrot-Perrus, M; Meilhac, O; Michel, JB | 1 |
| Ganz, P; Kinlay, S; Leslie, SJ; Libby, P; Olsson, AG; Rifai, N; Sasiela, WJ; Schwartz, GG; Szarek, M | 1 |
| Caselli, A; Economides, PA; Horton, ES; Khaodhiar, L; Tiani, E; Veves, A | 1 |
| Fang, CH; Li, JJ | 1 |
| Andreassen, AK; Aukrust, P; Gullestad, L; Hognestad, A; Holm, T; Kjekshus, JK; Semb, AG; Stokke, O; Wergeland, R | 1 |
| Akin, M; Aliyev, E; Altuglu, I; Ercan, E; Ercan, HE; Sekuri, C; Tengiz, I | 1 |
| Deev, AD; Gratsianskiĭ, NA; Pokrovskaia, EV; Vaulin, NA | 1 |
| Jono, S; Kizu, A; Koyama, H; Nishizawa, Y; Okuno, Y; Shioi, A | 1 |
| Egido, J; Tuñón, J | 1 |
| Emeis, SJ; Kleemann, R; Kooistra, T; Offerman, EH; Princen, HM; Szalai, AJ; Verschuren, L | 1 |
| Antoniades, C; Bosinakou, E; Kotsopoulou, M; Panagiotakos, D; Pitsavos, C; Stefanadis, C; Tousoulis, D; Vlachopoulos, C | 1 |
| Haskard, DO; Lunnon, MW; Mandryko, V; Naoumova, RP; Randi, AM; Wibaut-Berlaimont, V | 1 |
| Assaloni, R; Ceriello, A; Da Ros, R; Esposito, K; Giugliano, D; Maier, A; Piconi, L; Quagliaro, L | 1 |
| Antoniades, C; Bosinakou, E; Katsi, V; Kotsopoulou, M; Stefanadis, C; Tousoulis, D; Tsioufis, C | 1 |
| Blanco-Colio, LM; Egido, J; Gómez-Hernández, A; Hernández, G; Martín-Ventura, JL; Muñoz-García, B; Ortega, L; Serrano, J; Tuñón, J; Vega, M | 1 |
| Dohi, Y; Ohashi, M; Sato, K; Sugiyama, M; Takase, H; Ueda, R | 1 |
| Athyros, VG; Elisaf, M; Mikhailidis, DP | 1 |
| Aso, Y; Inukai, T; Inukai, Y; Matsumoto, S; Matsutomo, R; Takebayashi, K; Wakabayashi, S | 1 |
| Annovazzi, A; Arca, M; Bonanno, E; D'Alessandria, C; De Toma, G; Marcoccia, A; Scopinaro, F; Signore, A; Spagnoli, LG; Violi, F | 1 |
| Ferns, GA; Ghayour-Mobarhan, M; Lamb, DJ; Livingstone, C; Taylor, A; Vaidya, N; Wang, T | 1 |
| Bernard, D; De Backer, G; De Bacquer, D; De Buyzere, M; De Sutter, J; Jordaens, L; Langlois, M; Matthys, K; Tavernier, R; Van de Veire, NR | 1 |
| Nosaka, S; Ueki, M; Ushiroyama, T | 1 |
| Lawler, RL; Letterer, RA; Levy, WC; McDonald, GB; Minami, E; Mozaffarian, D | 1 |
| Bayés, B; Bonet, J; Granada, ML; Lauzurica, R; Llopis, MA; Navarro, M; Pastor, MC; Romero, R | 1 |
| Day, CA; Jacob, RF; Mason, RP; Walter, MF | 1 |
| Gupta, R; Lakshmy, R; Maulik, SK; Naik, N; Narang, D; Thomas, MK | 1 |
| Deng, P; Hong, SC; Nie, S; Wu, J; Wu, ZH; Zhao, SP; Zhou, HN | 1 |
| Chow, SC; Coward, WR; Marei, A; Vasa-Nicotera, MM; Yang, A | 1 |
| Bradbury, J | 1 |
| Hazen, SL; Nicholls, SJ; Nissen, SE; Ntanios, F; Schoenhagen, P; Sipahi, I; Tuzcu, EM; Wun, CC | 1 |
| Dörge, H; Grabedünkel, J; Liakopoulos, OJ; Nagorsnik, U; Schmitto, JD; Schoendube, FA | 1 |
| Busser, E; de Kleijn, DP; de Vries, JP; Koekkoek, JA; Moll, FL; Pasterkamp, G; Schoneveld, A; van der Wal, AC; Velema, E; Verheijen, JH; Verhoeven, BA; Virmani, R | 1 |
| Boudoulas, H; Stefanadi, E; Stefanadis, C; Toutouzas, K; Tsiamis, E; Tsioufis, C; Vavuranakis, M | 1 |
| Cunha, FQ; Cunha, TM; Ferreira, SH; Parada, CA; Poole, S; Santodomingo-Garzón, T; Valério, DA; Verri, WA | 1 |
| Chu, G; Ding, G; Jia, R; Tian, S | 1 |
| Ciccarelli, L; Corradi, L; Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Preti, P; Zoppi, A | 1 |
| Aizawa, Y; Fukaya, H; Imaki, R; Izumi, T; Kubo, T; Ohtaki, K; Ozaki, K; Ozaki, S; Shinagawa, H | 1 |
| Abad, S; Cachofeiro, V; de Vinuesa, SG; Goicoechea, M; Gómez-Campderá, F; Lahera, V; Luño, J; Vega, A | 1 |
| Alhan, CC; Avkaroğullari, M; Cayli, M; Demir, M; Demirtaş, M; Dönmez, Y; Inal, T; Kanadaşi, M; Koç, M; San, M; Usal, A | 1 |
| Li, M; Ren, H; Zhang, Y; Zhu, X | 1 |
| Arima, J; Iguro, Y; Kariyazono, H; Masuda, H; Nakamura, K; Sakata, R; Yamada, K | 1 |
| Gans, RO; May, JF; Mulder, DJ; Smit, AJ; Tervaert, JW; van Doormaal, JJ; van Haelst, PL; Wobbes, MH; Zijlstra, F | 1 |
| Ezhov, MV; Kukharchuk, VV; Naumov, VG; Samoĭlenko, EIu; Sergienko, IV; Tvorogova, MG | 1 |
| Dhayat, N; Dhayat, S; Du, J; Hilfiker-Kleiner, D; Laufs, U; Noutsias, M; Riad, A; Schultheiss, HP; Spillmann, F; Tschöpe, C; Van Linthout, S; Westermann, D | 1 |
| Erdogan, O; Ordulu, E | 1 |
| Adams, V; Doehner, W; Du, J; Mohr, Z; Pauschinger, M; Riad, A; Schultheiss, HP; Sobirey, M; Stiehl, S; Tschöpe, C; Westermann, D | 1 |
| Asher, J; Houston, M | 1 |
| Azzellino, A; Balestri, G; Cazzaniga, M; Cerrito, MG; Cusa, EN; DeCarlini, C; Ferrari, AU; Garducci, S; Guerra, L; Lavitrano, ML; Loardi, C; Mancia, G; Menicanti, L; Paolini, G; Radaelli, A; Santo, D | 1 |
| Amato, M; Arquati, M; Baldassarre, D; Brusoni, B; Camera, M; Cortellaro, M; Fiorentini, C; Montorsi, P; Porta, B; Romano, S; Tremoli, E | 1 |
| Anyakoha, NG; Barry, CE; Clarke, RM; Deighan, BF; Lynch, MA; Lyons, A; Nicolaou, A; O'Connell, F | 1 |
| Ganz, P; Kinlay, S; Libby, P; Olsson, AG; Rifai, N; Schwartz, GG; Szarek, M; Waters, DD | 1 |
| Kohno, K; Murata, Y; Sasaguri, Y; Tanimoto, A; Tsutsui, M; Wang, KY | 1 |
| Antoniades, C; Bosinakou, E; Katsi, V; Latsios, G; Marinou, K; Papageorgiou, N; Stefanadi, E; Stefanadis, C; Tousoulis, D; Triantafyllou, G; Tsioufis, C; Vavuranakis, E | 1 |
| Bergeron, J; Couture, P; Gagné, C; Hogue, JC; Lamarche, B; Tremblay, AJ | 1 |
| Kazantseva, MO; Logacheva, IV | 1 |
| De Angelis, S; De Lorenzo, A; Di Daniele, N; Di Renzo, L; Miani, N; Noce, A; Tozzo, C | 1 |
| Alcaino, H; Bustos, C; Castro, PF; Chiong, M; Gabrielli, LA; Garcia, L; Godoy, I; Greig, D; Lavandero, S; Mellado, R; Miranda, R; Verdejo, HE; Vukasovic, JL | 1 |
| Andalib, S; Garjani, A; Maleki-Dizaji, N; Ziaee, M | 1 |
| Ando, H; Fujimura, A; Kaneko, S; Saito, T; Sugimoto, K; Takamura, T; Tsuruoka, S; Yanagihara, H | 1 |
| Koenig, W | 1 |
| Ballantyne, CM; Davidson, MH; Hanefeld, M; Johnson, JL; Mohler, ER; Ruilope, LM; Zalewski, A | 1 |
| de Haan, W; de Vries-van der Weij, J; Gautier, T; Havekes, LM; Jukema, JW; Princen, HM; Rensen, PC; Romijn, JA; van der Hoogt, CC; van der Hoorn, JW; Westerterp, M | 1 |
| Aoki, M; Miyake, T; Morishita, R; Nishimura, M; Ogihara, T; Ohgi, S; Shiraya, S; Yoshikazu, F | 1 |
| Akalin, A; Akcar, N; Sensoy, B; Temiz, G | 1 |
| Bustos, C; Díaz, C; Egido, J; Hernández, G; Hernández-Presa, MA; Ortega, L; Ortego, M; Pérez, F; Tuñón, J | 1 |
| Bustos, C; Díaz, C; Egido, J; Hernández, G; Hernández-Presa, MA; Ortego, M; Tuñón, J | 1 |
| Park, A | 1 |
| Dorner, GT; Joukhadar, C; Klein, N; Prinz, M; Schmetterer, L; Schrolnberger, C; Vukovich, T; Wolzt, M | 1 |
| Grip, O; Janciauskiene, S; Lindgren, S | 1 |
| Hurt-Camejo, E; Mattsson-Hultén, L; Oscarsson, J; Wiklund, O | 1 |
7 review(s) available for atorvastatin and Inflammation
| Article | Year |
|---|---|
Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?
Topics: Acetylcysteine; Animals; Anticonvulsants; Antioxidants; Atorvastatin; Brain Injuries, Traumatic; Ceftriaxone; Dibenzazepines; Drug Repositioning; Epilepsy; Epilepsy, Post-Traumatic; Erythropoietin; Fingolimod Hydrochloride; GABA Agents; Gabapentin; Humans; Immunologic Factors; Inflammation; Interleukin 1 Receptor Antagonist Protein; Isoflurane; Levetiracetam; Losartan; Neuroprotective Agents; Oxidative Stress; Pregabalin; Pyrrolidinones; Sirolimus; Stroke; Topiramate; Translational Research, Biomedical; Vigabatrin | 2020 |
Pathophysiology and Nonsurgical Treatment of Chronic Subdural Hematoma: From Past to Present to Future.
Topics: Angiogenesis Inducing Agents; Animals; Atorvastatin; Cytokines; Hematoma, Subdural, Chronic; Humans; Inflammation; Subdural Space | 2018 |
Can statins suppress the development of abdominal aortic aneurysms? A review of the current evidence.
Topics: Animals; Aortic Aneurysm, Abdominal; Atorvastatin; Blood Vessels; Cardiovascular Agents; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Matrix Metalloproteinases; Models, Animal; Pyrroles; Risk Assessment; Simvastatin | 2010 |
Statin loading for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cytokines; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Oxidative Stress; Preoperative Care; Pyrroles; Time Factors | 2010 |
Statin loading before percutaneous coronary intervention: proposed mechanisms and applications.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Biomarkers, Pharmacological; Confidence Intervals; Endothelium, Vascular; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Inflammation; Kidney Diseases; Multivariate Analysis; Myocardial Infarction; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2010 |
Pitavastatin: an overview.
Topics: Antioxidants; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Endothelium, Vascular; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Japan; Metabolic Syndrome; Molecular Structure; Multicenter Studies as Topic; Plaque, Atherosclerotic; Pyrroles; Quinolines; Receptors, LDL | 2011 |
Statins and C-reactive protein levels.
Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Pyrroles; Risk Factors | 2007 |
85 trial(s) available for atorvastatin and Inflammation
| Article | Year |
|---|---|
The effects of atorvastatin on emotional processing, reward learning, verbal memory and inflammation in healthy volunteers: An experimental medicine study.
Topics: Adolescent; Adult; Atorvastatin; Biomedical Research; C-Reactive Protein; Depression; Double-Blind Method; Emotions; Facial Recognition; Fear; Female; Healthy Volunteers; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Reward; Social Perception; Verbal Learning; Young Adult | 2021 |
Atorvastatin for unruptured intracranial vertebrobasilar dissecting aneurysm (ATREAT-VBD): protocol for a randomised, double-blind, blank-controlled trial.
Topics: Aortic Dissection; Atorvastatin; Double-Blind Method; Humans; Inflammation; Randomized Controlled Trials as Topic | 2022 |
Rationale and design of COLchicine On-admission to Reduce inflammation in Acute Coronary Syndrome (COLOR-ACS) study.
Topics: Acute Coronary Syndrome; Atorvastatin; C-Reactive Protein; Colchicine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Treatment Outcome | 2023 |
Effect of statins on inflammation and cardiac function in patients with chronic Chagas disease: A protocol for pathophysiological studies in a multicenter, placebo-controlled, proof-of-concept phase II trial.
Topics: Atorvastatin; Chagas Disease; Clinical Trials, Phase II as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Multicenter Studies as Topic; Nitroimidazoles; Persistent Infection; Randomized Controlled Trials as Topic; Trypanocidal Agents; Trypanosoma cruzi | 2023 |
An open label randomized controlled trial of atorvastatin versus aspirin in elite controllers and antiretroviral-treated people with HIV.
Topics: Anti-Retroviral Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Inflammation; Male; Middle Aged; Viral Load | 2023 |
A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV.
Topics: Adult; Anti-HIV Agents; Anticholesteremic Agents; Atorvastatin; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; HIV Infections; HIV Protease Inhibitors; Humans; Immunosenescence; Inflammation; Lymphocyte Activation; Male; Middle Aged; Pilot Projects; Raltegravir Potassium | 2020 |
Effect of Prior Atorvastatin Treatment on the Frequency of Hospital Acquired Pneumonia and Evolution of Biomarkers in Patients with Acute Ischemic Stroke: A Multicenter Prospective Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Calcitonin; Cross Infection; Female; Glasgow Coma Scale; Humans; Inflammation; Intensive Care Units; Interleukin-6; Male; Middle Aged; Pneumonia, Ventilator-Associated; Prospective Studies; Stroke; Tumor Necrosis Factor-alpha | 2017 |
The effect of fasting status on lipids, lipoproteins, and inflammatory biomarkers assessed after hospitalization for an acute coronary syndrome: Insights from PROVE IT-TIMI 22.
Topics: Acute Coronary Syndrome; Atorvastatin; Biomarkers; Colorimetry; Dose-Response Relationship, Drug; Fasting; Female; Follow-Up Studies; Hospitalization; Humans; Immunoturbidimetry; Inflammation; Lipids; Lipoproteins; Male; Middle Aged; Pravastatin; Prognosis; Retrospective Studies | 2018 |
Brief Report: Statin Effects on Myocardial Fibrosis Markers in People Living With HIV.
Topics: Adolescent; Adult; Amino Acids; Atorvastatin; Biomarkers; Blood Proteins; Coronary Artery Disease; Double-Blind Method; Female; Fibrosis; Galectin 3; Galectins; Growth Differentiation Factor 15; HIV; HIV Infections; Humans; Inflammation; Interleukin-1 Receptor-Like 1 Protein; Interleukin-6; Lipoproteins, LDL; Male; Middle Aged; Receptors, Interleukin-1; Young Adult | 2018 |
Anti-Inflammatory Effect of Atorvastatin on the Kidney Graft of Living Donor Transplants.
Topics: Adult; Anti-Inflammatory Agents; Atorvastatin; C-Reactive Protein; Female; Graft Survival; Humans; Inflammation; Kidney Transplantation; Living Donors; Male; Middle Aged; Young Adult | 2018 |
Coenzyme Q10 in acute influenza.
Topics: Acute Disease; Adult; Atorvastatin; Biomarkers; Double-Blind Method; Female; Humans; Inflammation; Influenza, Human; Male; Middle Aged; Severity of Illness Index; Statistics, Nonparametric; Tertiary Care Centers; Ubiquinone; Young Adult | 2019 |
Administration of a loading dose of atorvastatin before percutaneous coronary intervention prevents inflammation and reduces myocardial injury in STEMI patients: a randomized clinical study.
Topics: Aged; Atorvastatin; C-Reactive Protein; Combined Modality Therapy; Echocardiography; Female; Heptanoic Acids; Humans; Inflammation; Male; Matrix Metalloproteinase 9; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Percutaneous Coronary Intervention; Prospective Studies; Pyrroles; Ventricular Function, Left | 2013 |
Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Desmosterol; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Phytosterols; Prospective Studies; Pyrroles; Risk Factors; Sitosterols; Statistics, Nonparametric | 2013 |
The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy--5-year follow-up.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Cardiomyopathy, Dilated; Cytokines; Female; Follow-Up Studies; Heptanoic Acids; Hospitalization; Humans; Inflammation; Male; Middle Aged; Pyrroles; Uric Acid; Ventricular Function, Left | 2013 |
Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study.
Topics: Adult; Aged; Aged, 80 and over; Aorta, Thoracic; Atherosclerosis; Atorvastatin; Carotid Arteries; Double-Blind Method; Feasibility Studies; Female; Fluorodeoxyglucose F18; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Multimodal Imaging; Plaque, Atherosclerotic; Positron-Emission Tomography; Pyrroles; Treatment Outcome | 2013 |
[Prevention of cardiovascular complications in patients undergoing aortic-iliac reconstructions by correction of inflammation and endotoxemia].
Topics: Aorta, Abdominal; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Endotoxemia; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iliac Artery; Inflammation; Middle Aged; Postoperative Complications; Pyrroles; Treatment Outcome; Vascular Surgical Procedures | 2013 |
High-dose atorvastatin reduces periodontal inflammation: a novel pleiotropic effect of statins.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Periodontal Diseases; Pyrroles; Treatment Outcome | 2013 |
Intensive Atorvastatin Therapy Attenuates the Inflammatory Responses in Monocytes of Patients with Unstable Angina Undergoing Percutaneous Coronary Intervention via Peroxisome Proliferator-Activated Receptor γ Activation.
Topics: Aged; Angina, Unstable; Atorvastatin; Cells, Cultured; Female; Humans; Inflammation; Inflammation Mediators; Male; Middle Aged; Monocytes; Percutaneous Coronary Intervention; PPAR gamma | 2015 |
The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial.
Topics: Aged; Anti-Inflammatory Agents; Aortic Diseases; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Artery Diseases; Double-Blind Method; Female; Fluorodeoxyglucose F18; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Male; Middle Aged; Multimodal Imaging; p38 Mitogen-Activated Protein Kinases; Plaque, Atherosclerotic; Positron-Emission Tomography; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrroles; Radiopharmaceuticals; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Triazines; United States | 2015 |
Differential Effects of Atorvastatin and Pitavastatin on Inflammation, Insulin Resistance, and the Carotid Intima-Media Thickness in Patients with Dyslipidemia.
Topics: Aged; Atorvastatin; Carotid Artery Diseases; Carotid Intima-Media Thickness; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Insulin Resistance; Male; Prognosis; Prospective Studies; Quinolines | 2015 |
Early High-dosage Atorvastatin Treatment Improved Serum Immune-inflammatory Markers and Functional Outcome in Acute Ischemic Strokes Classified as Large Artery Atherosclerotic Stroke: A Randomized Trial.
Topics: Acute Disease; Aged; Atorvastatin; Biomarkers; Brain Ischemia; E-Selectin; Female; Humans; Inflammation; Inflammation Mediators; Intercellular Adhesion Molecule-1; Interleukin-10; Interleukin-1beta; Interleukin-6; Intracranial Arteriosclerosis; Male; Middle Aged; P-Selectin; Stroke; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2016 |
Prevention of atrial fibrillation and inflammatory response after on-pump coronary artery bypass using different statin dosages: a randomized, controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Atrial Fibrillation; Biomarkers; C-Reactive Protein; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Elective Surgical Procedures; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Inflammation; Interleukin-6; Male; Middle Aged; Postoperative Complications; Preoperative Care; Prospective Studies; Treatment Outcome | 2016 |
Zhibitai and low-dose atorvastatin reduce blood lipids and inflammation in patients with coronary artery disease.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Coronary Artery Disease; Cytokines; Drugs, Chinese Herbal; Female; Humans; Inflammation; Lipids; Male; Medicine, Chinese Traditional; Middle Aged | 2017 |
Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Atorvastatin; Biomarkers; Blood Glucose; Cholesterol; Curcumin; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Oxidative Stress; Pyrroles; Triglycerides | 2008 |
Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Dose-Response Relationship, Drug; F2-Isoprostanes; Female; Heptanoic Acids; Humans; Inflammation; Male; Matrix Metalloproteinase 9; Metabolic Syndrome; Middle Aged; Monocytes; NF-kappa B; Oxidative Stress; Polyethylene; Pyrroles; Superoxides; Tyrosine | 2008 |
Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cause of Death; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Inflammation; Middle Aged; Placebos; Predictive Value of Tests; Pyrroles; Renal Dialysis; Survival Rate; Treatment Outcome; Young Adult | 2008 |
Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFAST.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; CD40 Ligand; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Inflammation; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Triglycerides | 2008 |
Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment.
Topics: Aged; Atherosclerosis; Atorvastatin; Biomarkers; Blood Coagulation; Carotid Artery Diseases; Coronary Disease; Cross-Sectional Studies; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Myocardial Infarction; Plasma; Pyrroles; Sample Size; Thrombosis; Ultrasonography | 2009 |
Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Chi-Square Distribution; Dose-Response Relationship, Drug; Electrophoresis, Gel, Two-Dimensional; Female; Gene Expression; Gene Expression Profiling; Heat-Shock Proteins; Heptanoic Acids; Humans; Inflammation; Lipids; Male; Middle Aged; Monocytes; Pyrroles; Statistics, Nonparametric; Tandem Mass Spectrometry; Thrombosis | 2009 |
Short-term 20-mg atorvastatin therapy reduces key inflammatory factors including c-Jun N-terminal kinase and dendritic cells and matrix metalloproteinase expression in human abdominal aortic aneurysmal wall.
Topics: Aged; Aged, 80 and over; Aortic Aneurysm, Abdominal; Atorvastatin; Cell Proliferation; Dendritic Cells; Female; Heptanoic Acids; Humans; Inflammation; JNK Mitogen-Activated Protein Kinases; Male; Matrix Metalloproteinases; Middle Aged; Muscle, Smooth, Vascular; Pyrroles; Tissue Inhibitor of Metalloproteinase-1 | 2009 |
The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Carotid Arteries; Carotid Stenosis; Contrast Media; Dextrans; Double-Blind Method; Female; Ferrosoferric Oxide; Heptanoic Acids; Humans; Inflammation; Iron; Macrophages; Magnetic Resonance Imaging; Magnetite Nanoparticles; Male; Middle Aged; Nanoparticles; Oxides; Pyrroles | 2009 |
Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardia
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Autoantibodies; Biomarkers; Cholesterol, LDL; Cohort Studies; Female; Heptanoic Acids; Humans; Immunoglobulin G; Immunoglobulin M; Inflammation; Lipoprotein(a); Male; Middle Aged; Oxidation-Reduction; Phospholipids; Pyrroles; Reactive Oxygen Species; Risk Factors; Thromboembolism | 2009 |
Atorvastatin improves endothelial function and cardiac performance in patients with dilated cardiomyopathy: the role of inflammation.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Cardiomyopathy, Dilated; Cholesterol; Double-Blind Method; Endothelium, Vascular; Exercise; Exercise Test; Female; Heart Function Tests; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Intercellular Adhesion Molecule-1; Male; Middle Aged; Myocardial Contraction; Prospective Studies; Pyrroles; Vasodilation; Ventricular Function, Left; Young Adult | 2009 |
Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Inflammation; Male; Prospective Studies; Pyrroles; Renal Dialysis | 2009 |
Combined effects of atorvastatin and metformin on glucose-induced variations of inflammatory process in patients with diabetes mellitus.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypoglycemic Agents; Inflammation; Male; Metformin; Middle Aged; Pyrroles; Treatment Outcome; Tumor Necrosis Factor-alpha | 2011 |
Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: A prospective, randomized study.
Topics: Adult; Atorvastatin; C-Reactive Protein; Fasting; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperandrogenism; Inflammation; Insulin; Insulin Resistance; Luteinizing Hormone; Oxidative Stress; Polycystic Ovary Syndrome; Prospective Studies; Pyrroles; Simvastatin; Testosterone; Young Adult | 2010 |
Genome-wide association of lipid-lowering response to statins in combined study populations.
Topics: Adult; Aged; Atorvastatin; Bayes Theorem; Cholesterol; Female; Genome-Wide Association Study; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Phenotype; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Simvastatin | 2010 |
Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atherosclerosis; Atorvastatin; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Observation; Pravastatin; Pyrroles; Treatment Outcome | 2010 |
Short-term treatment with high-dose atorvastatin reduces LDL cholesterol but shows no anti-inflammatory effects in normolipidemic subjects with normal CRP levels.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Leukocytes; Male; Middle Aged; Pyrroles; Young Adult | 2010 |
Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Carrier Proteins; Dose-Response Relationship, Drug; Enzymes; Female; Fluorobenzenes; Heptanoic Acids; Humans; Inflammation; Lipid Metabolism; Lipoproteins; Male; Maximum Tolerated Dose; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2010 |
Continuation of statin therapy in patients with presumed infection: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cholesterol; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Hospital Mortality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Prospective Studies; Pyrroles; Sepsis; Severity of Illness Index; Treatment Outcome | 2011 |
Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis.
Topics: Adiponectin; Adult; Aged; Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Atorvastatin; Drug Therapy, Combination; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Methotrexate; Middle Aged; Prednisone; Pyrroles; Regional Blood Flow; Resistin; Risk Factors; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2011 |
Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Androgens; Anticholesteremic Agents; Atorvastatin; Blood Vessels; Double-Blind Method; Female; Heptanoic Acids; Humans; Inflammation; Placebos; Polycystic Ovary Syndrome; Pregnancy; Pyrroles; Young Adult | 2011 |
Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Atorvastatin; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Fibric Acids; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Phospholipases A2; Phospholipases A2, Secretory; Pyrroles | 2011 |
Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial.
Topics: Acetates; Acute Coronary Syndrome; Atorvastatin; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Inflammation; Keto Acids; Phospholipases A2, Secretory; Pyrroles | 2012 |
STAR VaS--Short Term Atorvastatin Regime for Vasculopathic Subjects: a randomized placebo-controlled trial evaluating perioperative atorvastatin therapy in noncardiac surgery.
Topics: Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Perioperative Care; Postoperative Complications; Pyrroles; Risk Factors; Surgical Procedures, Operative | 2012 |
Impact of intensive statin use on the level of inflammation and platelet activation in stable angina after percutaneous coronary intervention: a clinical study.
Topics: Aged; Angina Pectoris; Animals; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Premedication; Prospective Studies; Pyrroles; Reoperation; Single-Blind Method; Stents | 2013 |
Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Carotid Artery Diseases; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipoproteins; Macrophages; Male; Middle Aged; Prospective Studies; Pyrroles; Thromboplastin; Thrombosis | 2002 |
Statins promote potent systemic antioxidant effects through specific inflammatory pathways.
Topics: Antioxidants; Arteriosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipoproteins; Male; Middle Aged; Oxidation-Reduction; Prospective Studies; Pyrroles; Reactive Oxygen Species; Signal Transduction; Statistics, Nonparametric; Tyrosine | 2003 |
[Markers of inflammation and platelet aggregation in patients with non ST elevation acute coronary syndrome treated with atorvastatin or pravastatin].
Topics: Acute Disease; Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Coronary Disease; Drug Administration Schedule; Electrocardiography; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Male; Middle Aged; Platelet Aggregation; Pravastatin; Pyrroles; Time Factors | 2003 |
High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
Topics: Acute Disease; Aged; Angina, Unstable; Apolipoproteins; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Myocardial Infarction; Pyrroles; Serum Amyloid A Protein; Syndrome; Troponin | 2003 |
The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes.
Topics: Adult; Atorvastatin; Biomarkers; Brachial Artery; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Microcirculation; Middle Aged; Nitroglycerin; Pyrroles; Regional Blood Flow; Risk Factors; Skin; Vasodilation; Vasodilator Agents | 2004 |
Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation.
Topics: Arteriosclerosis; Atorvastatin; C-Reactive Protein; Chronic Disease; Coronary Artery Disease; E-Selectin; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Nitric Oxide; Pyrroles; Simvastatin; Treatment Outcome | 2004 |
Atorvastatin treatment decreases inflammatory and proteolytic activity in patients with hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Male; Matrix Metalloproteinase 9; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2004 |
[Relationship Between Lipid Lowering and Changes of Hemostasis and Inflammation During Use of Statins in Non-ST Elevation Acute Coronary Syndrome].
Topics: Acute Coronary Syndrome; Atorvastatin; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids | 2004 |
Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cytokines; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Female; Forearm; Heart Failure; Heptanoic Acids; Humans; Hyperemia; Inflammation; Male; Middle Aged; Pyrroles; Regional Blood Flow; Vascular Cell Adhesion Molecule-1 | 2005 |
Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Biphenyl Compounds; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperglycemia; Hypertriglyceridemia; Inflammation; Irbesartan; Male; Middle Aged; Oxidative Stress; Postprandial Period; Pyrroles; Tetrazoles; Treatment Outcome | 2005 |
The impact of early administration of low-dose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Chemokine CCL2; Cholesterol; Female; Heptanoic Acids; Humans; Inflammation; Interleukin-6; Male; Middle Aged; Prospective Studies; Pyrroles; Time Factors; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2006 |
Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month.
Topics: Aged; Anti-Inflammatory Agents; Atherosclerosis; Atorvastatin; Blotting, Southern; Blotting, Western; Carotid Arteries; Chemokine CCL2; Cyclooxygenase 2; Dinoprostone; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Processing, Computer-Assisted; Immunohistochemistry; Inflammation; Leukocytes, Mononuclear; Lipids; Male; Middle Aged; NF-kappa B; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2005 |
Inflammatory markers and the metabolic syndrome.
Topics: Antihypertensive Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hypolipidemic Agents; Inflammation; Lactones; Leukocyte Count; Metabolic Syndrome; Metformin; Orlistat; Prospective Studies; Pyrroles; Treatment Outcome | 2005 |
The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein-1 in patients with type 2 diabetes complicated by hyperlipidemia.
Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Chemokine CCL2; Diabetes Mellitus, Type 2; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles | 2005 |
Coronary risk factors and inflammation in patients with coronary artery disease and internal cardioverter defibrillator implants.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Belgium; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Defibrillators, Implantable; Double-Blind Method; Female; Follow-Up Studies; Glycated Hemoglobin; Greece; Heptanoic Acids; Humans; Inflammation; Inflammation Mediators; Lipids; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prevalence; Pyrroles; Research Design; Risk Factors; Tachycardia, Ventricular; Treatment Outcome; Ventricular Fibrillation | 2006 |
Short-term effects of low-dose atorvastatin on inflammatory status and lipid profiles in perimenopausal hypercholesterolemic, hypertriglyceridemic women.
Topics: Adult; Atorvastatin; Blood Coagulation; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Female; Fibrinolysis; Gonadal Steroid Hormones; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Inflammation; Lipids; Lipoproteins; Malondialdehyde; Middle Aged; Plasminogen Activator Inhibitor 1; Postmenopause; Premenopause; Prospective Studies; Pyrroles; Time Factors; Tissue Plasminogen Activator; Triglycerides | 2006 |
The effects of atorvastatin (10 mg) on systemic inflammation in heart failure.
Topics: Adult; Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Cross-Over Studies; Double-Blind Method; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Pyrroles; Receptors, Tumor Necrosis Factor, Type I; Treatment Outcome | 2005 |
Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
Topics: Adiponectin; Adult; Atorvastatin; Biomarkers; Blood Glucose; C-Reactive Protein; Dyslipidemias; Female; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Kidney Transplantation; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Tumor Necrosis Factor-alpha | 2005 |
Correlation between inflammation and oxidative stress in normocholesterolemic coronary artery disease patients 'on' and 'off' atorvastatin for short time intervals.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol; Coronary Artery Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Oxidative Stress; Pyrroles; Thiobarbituric Acid Reactive Substances | 2006 |
[Atorvastatin reduces the expression of COX-2 mRNA in peripheral blood monocytes in patients with acute myocardial infarction and modulates the early inflammatory response].
Topics: Aged; Atorvastatin; Cyclooxygenase 2; Female; Heptanoic Acids; Humans; Inflammation; Interleukin-6; Leukocytes, Mononuclear; Male; Middle Aged; Myocardial Infarction; Pyrroles; RNA, Messenger | 2005 |
Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Body Mass Index; C-Reactive Protein; Coronary Disease; Coronary Vessels; Disease Progression; Endosonography; Female; Heptanoic Acids; Humans; Inflammation; Lipids; Male; Middle Aged; Obesity; Pravastatin; Pyrroles; Risk Factors | 2006 |
Relation between local temperature and C-reactive protein levels in patients with coronary artery disease: effects of atorvastatin treatment.
Topics: Aged; Atorvastatin; Body Temperature; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Inflammation; Male; Middle Aged; Pyrroles; Thermography | 2007 |
Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients.
Topics: Adult; Aged; Amlodipine; Atorvastatin; Biomarkers; Blood Glucose; Body Mass Index; Calcium Channel Blockers; Cholesterol; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Inflammation; Insulin Resistance; Interleukin-6; Male; Middle Aged; Obesity; Pyrroles; Tablets; Tumor Necrosis Factor-alpha | 2006 |
Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Chronic Disease; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fibrinogen; Fibrinolysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Kidney Diseases; Lipid Metabolism; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prospective Studies; Pyrroles; Tissue Plasminogen Activator | 2006 |
Effects of atorvastatin and aspirin combined therapy on inflammatory responses in patients undergoing coronary artery bypass grafting.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antithrombins; Aspirin; Atorvastatin; Blood Platelets; Cholesterol; Coronary Artery Bypass; Cytokines; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Inflammation; Male; Middle Aged; P-Selectin; Pyrroles; Receptors, Cytokine; Thrombin; Thromboxane B2; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2006 |
The effect of aggressive versus conventional lipid-lowering therapy on markers of inflammatory and oxidative stress.
Topics: Adult; Aged; Antibodies; Atorvastatin; Biomarkers; C-Reactive Protein; Cell Adhesion Molecules; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipoproteins, LDL; Male; Middle Aged; Neopterin; Oxidative Stress; Pyrroles; Simvastatin; von Willebrand Factor | 2007 |
Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Chemokine CCL2; Cholesterol; Diabetes Complications; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Inflammation; Intercellular Adhesion Molecule-1; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2007 |
[Effect of therapy with atorvastatin on parameters of postprandial lipemia and factors of inflammation in patients with ischemic heart disease].
Topics: Adult; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Inflammation; Lipids; Male; Myocardial Ischemia; Postprandial Period; Pyrroles; Treatment Outcome | 2007 |
Early effects of low versus high dose atorvastatin treatment on coagulation and inflammation parameters in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Atorvastatin; Blood Coagulation; C-Reactive Protein; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Pyrroles | 2008 |
Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor combination.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Atorvastatin; Coronary Artery Bypass; Coronary Artery Disease; Coronary Circulation; Creatine Kinase; Dose-Response Relationship, Drug; E-Selectin; Enalapril; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Interleukin-6; Leukocyte Count; Male; Middle Aged; Platelet Count; Pyrroles; Ramipril; Simvastatin; Stroke Volume; Time Factors; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1; von Willebrand Factor | 2007 |
Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Pyrroles; Risk Factors; ROC Curve; Serum Amyloid A Protein; Stroke | 2008 |
Early initiation of low-dose atorvastatin treatment after an acute ST-elevated myocardial infarction, decreases inflammatory process and prevents endothelial injury and activation.
Topics: Atorvastatin; Biomarkers; Electrocardiography; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Myocardial Infarction; Plasminogen Activator Inhibitor 1; Pyrroles; Time Factors; Tissue Plasminogen Activator; Vascular Cell Adhesion Molecule-1; von Willebrand Factor | 2009 |
Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.
Topics: Atorvastatin; Biomarkers; Cell Adhesion Molecules; Diabetes Mellitus, Type 2; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Inflammation; Lipids; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Pyrroles | 2008 |
[Immunoinflammatory factors in unstable angina. Possibility of influence of atorvastatin].
Topics: Angina, Unstable; Atorvastatin; C-Reactive Protein; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Cellular; Inflammation; Interleukin-4; Male; Middle Aged; Pyrroles; T-Lymphocytes; Treatment Outcome; Tumor Necrosis Factor-alpha | 2007 |
Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients.
Topics: Adipokines; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Blood Glucose; Cross-Over Studies; Female; Glucose Intolerance; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Male; Middle Aged; Pravastatin; Pyrroles | 2008 |
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-bl
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Benzaldehydes; Biomarkers; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukins; Male; Middle Aged; Oximes; Prognosis; Pyrroles; Recurrence; Risk Factors | 2008 |
Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipids; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Therapeutic Equivalency; Thrombophilia; Treatment Outcome | 2001 |
Effects of simvastatin and atorvastatin on inflammation markers in plasma.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-6; Male; Middle Aged; Pyrroles; Simvastatin | 2002 |
190 other study(ies) available for atorvastatin and Inflammation
| Article | Year |
|---|---|
Topics: Animals; Anti-Inflammatory Agents; Asteraceae; Atorvastatin; Blood Pressure; Carotid Intima-Media Thickness; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Ethanol; Female; Inflammation; Plant Extracts; Postmenopause; Rats; Rats, Sprague-Dawley; Vasoconstriction; Vasodilation | 2021 |
Dexamethasone enhances the efficacy of atorvastatin in inhibiting excessively inflammation-induced abnormal angiogenesis by regulating macrophages.
Topics: Atorvastatin; Dexamethasone; Glucocorticoids; Humans; Inflammation; Macrophages | 2021 |
Atorvastatin-Induced Absorption of Chronic Subdural Hematoma Is Partially Attributed to the Polarization of Macrophages.
Topics: Animals; Atorvastatin; Hematoma, Subdural, Chronic; Inflammation; Macrophages; Magnetic Resonance Imaging; Rats | 2022 |
Atorvastatin combined with dexamethasone promote hematoma absorption in an optimized rat model of chronic subdural hematoma.
Topics: Animals; Atorvastatin; Cytokines; Dexamethasone; Disease Models, Animal; Hematoma, Subdural, Chronic; Inflammation; Neovascularization, Physiologic; Rats | 2021 |
Atorvastatin suppresses NLRP3 inflammasome activation in intracerebral hemorrhage via TLR4- and MyD88-dependent pathways.
Topics: Animals; Atorvastatin; Cerebral Hemorrhage; Cytokines; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Mice; Mice, Inbred C57BL; Myeloid Differentiation Factor 88; Neurons; NLR Family, Pyrin Domain-Containing 3 Protein; Signal Transduction; Toll-Like Receptor 4 | 2022 |
Combined atorvastatin and pentoxifylline in ameliorating inflammation induced by complete Freund's adjuvant.
Topics: Animals; Arthritis, Experimental; Atorvastatin; Forkhead Transcription Factors; Freund's Adjuvant; Inflammation; Pentoxifylline; Rats; Rats, Wistar | 2022 |
Effects of metformin, letrozole and atorvastatin on inflammation and apoptosis in experimental peritoneal and ovarian endometriosis in the rat.
Topics: Animals; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Endometriosis; Female; Humans; Inflammation; Interleukin-6; Interleukin-8; Ki-67 Antigen; Letrozole; Metformin; Proto-Oncogene Proteins c-bcl-2; Rats; Tumor Necrosis Factor-alpha | 2022 |
Peripheral Monocyte Percentage as a Potential Indicator of Prognosis in Patients with Chronic Subdural Hematoma Receiving Conservative Therapy.
Topics: Atorvastatin; Conservative Treatment; Dexamethasone; Hematoma, Subdural, Chronic; Humans; Inflammation; Monocytes; Prognosis; Retrospective Studies; Treatment Outcome | 2022 |
Thyroid Antibody Titers and Hypothalamic-Pituitary-Thyroid Axis Activity in Levothyroxine-Treated Women With Autoimmune Subclinical Hypothyroidism Receiving Atorvastatin or Metformin.
Topics: Atorvastatin; C-Reactive Protein; Female; Hashimoto Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypothyroidism; Inflammation; Insulin Resistance; Metformin; Thyroid Hormones; Thyrotropin; Thyroxine | 2022 |
RNA Sequencing Reveals Beneficial Effects of Atorvastatin on Endothelial Cells in Acute Kawasaki Disease.
Topics: Atorvastatin; Endothelial Cells; Human Umbilical Vein Endothelial Cells; Humans; Immunoglobulins, Intravenous; Inflammation; Infliximab; Mucocutaneous Lymph Node Syndrome; Sequence Analysis, RNA | 2022 |
Pleiotropic effects of pitavastatin: a pilot study using the saphenous vein endothelial cell model of endothelial injury and prevention of atherosclerosis.
Topics: Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cytokines; Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Pilot Projects; Quinolines; Saphenous Vein; Tumor Necrosis Factor-alpha | 2022 |
Impact of atorvastatin on plasma and cardiac biomarkers of inflammation, oxidative stress, and fibrosis in a rat model of streptozotocin-induced diabetes.
Topics: Animals; Atorvastatin; Biomarkers; Diabetes Mellitus, Experimental; Fibrosis; Inflammation; Male; Nitrites; Oxidants; Oxidative Stress; Rats; Rats, Wistar; Streptozocin; Thiobarbituric Acid Reactive Substances | 2023 |
IL-1β inhibition combined with cholesterol-lowering therapies decreases synovial lining thickness and spontaneous cartilage degeneration in a humanized dyslipidemia mouse model.
Topics: Animals; Atorvastatin; Cartilage; Cholesterol; Disease Models, Animal; Dyslipidemias; Female; Inflammation; Mice; Osteoarthritis; Proprotein Convertase 9; Synovitis | 2023 |
Syringeable atorvastatin loaded eugenol enriched PEGylated cubosomes in-situ gel for the intra-pocket treatment of periodontitis: statistical optimization and clinical assessment.
Topics: Atorvastatin; Eugenol; Humans; Inflammation; Particle Size; Periodontitis; Polyethylene Glycols | 2023 |
Atorvastatin attenuates allergic inflammation by blocking prostaglandin biosynthesis in rats with allergic rhinitis.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Cytokines; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mice; Mice, Inbred BALB C; Nasal Mucosa; NF-kappa B; Ovalbumin; Prostaglandins; Rats; Rhinitis, Allergic | 2023 |
Effect of atorvastatin on lipoxygenase pathway-related gene expression in an in vitro model of lipid accumulation in hepatocytes.
Topics: Atorvastatin; Gene Expression; Hepatocytes; Humans; Inflammation; Lipoxygenase; Lipoxygenases; Palmitic Acid; Phospholipases A2, Cytosolic | 2023 |
Statins change the cytokine profile in
Topics: Animals; Atorvastatin; Cardiomyopathies; Chagas Disease; Cytokines; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Macrophages; Mice; NF-kappa B; rho-Associated Kinases; Trypanosoma cruzi; U937 Cells | 2022 |
Atorvastatin Attenuates Diet-Induced Non-Alcoholic Steatohepatitis in APOE*3-Leiden Mice by Reducing Hepatic Inflammation.
Topics: Animals; Apolipoproteins E; Atorvastatin; Cholesterol; Diet; Inflammasomes; Inflammation; Liver; Liver Cirrhosis; Mice; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Non-alcoholic Fatty Liver Disease | 2023 |
Effects of atorvastatin in suppressing pulmonary vascular remodeling in rats with chronic obstructive pulmonary disease.
Topics: Animals; Atorvastatin; Female; Inflammation; Lung; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Sprague-Dawley; Vascular Endothelial Growth Factor A; Vascular Remodeling | 2023 |
Oxidized dietary lipids induce vascular inflammation and atherogenesis in post-menopausal rats: estradiol and selected antihyperlipidemic drugs restore vascular health in vivo.
Topics: Animals; Atherosclerosis; Atorvastatin; Cholesterol; Diet; Estradiol; Estrogens; Female; Humans; Hypolipidemic Agents; Inflammation; Lipids; Nitric Oxide; Ovariectomy; Postmenopause; Rats; Tumor Necrosis Factor-alpha | 2023 |
DL-3-n-butylphthalide improves the endothelium-dependent vasodilation in high-fat diet-fed ApoE
Topics: Animals; Apolipoproteins E; Apoptosis; Atherosclerosis; Atorvastatin; Cytokines; Diet, High-Fat; Endothelium; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Ischemic Stroke; Male; Mice; Mice, Knockout; Necroptosis; Vasodilation | 2023 |
A synergistic strategy of dual-crosslinking and loading intelligent nanogels for enhancing anti-coagulation, pro-endothelialization and anti-calcification properties in bioprosthetic heart valves.
Topics: Animals; Anti-Inflammatory Agents; Anticoagulants; Atorvastatin; Bioprosthesis; Calcinosis; Glutaral; Heart Valve Prosthesis; Heart Valves; Heparin; Hydrogen Peroxide; Inflammation; Nanogels; Schiff Bases; Sulfonic Acids; Swine; Thrombosis | 2023 |
A novel circular RNA, circSQSTM1, protects the endothelial function in atherosclerosis.
Topics: Animals; Atherosclerosis; Atorvastatin; Endothelial Cells; In Situ Hybridization, Fluorescence; Inflammation; Mice; RNA, Circular; Sirtuin 1 | 2023 |
Inhibition of EphA2 protects against atherosclerosis by synergizing with statins to mitigate macrophage inflammation.
Topics: Animals; Atherosclerosis; Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Macrophages; Mice; Plaque, Atherosclerotic | 2023 |
Atorvastatin increases the production of proinflammatory cytokines and decreases the survival of Escherichia coli-infected mice.
Topics: Animals; Atorvastatin; Escherichia coli; Escherichia coli Infections; Female; Gene Expression Regulation; Immunosuppressive Agents; Inflammation; Interferon-gamma; Interleukin-10; Interleukin-13; Interleukin-4; Interleukin-6; Leukocytes, Mononuclear; Lipopolysaccharides; Male; Mice; Primary Cell Culture; Survival Analysis; Tumor Necrosis Factor-alpha | 2019 |
Atorvastatin Induces Hepatotoxicity in Diabetic Rats via Oxidative Stress, Inflammation, and Anti-Apoptotic Pathway.
Topics: Animals; Antioxidants; Apoptosis; Atorvastatin; Blood Glucose; Chemical and Drug Induced Liver Injury; China; Diabetes Mellitus, Experimental; Hepatocytes; Inflammation; Liver; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley; Signal Transduction; Superoxide Dismutase | 2019 |
Atorvastatin ameliorates depressive behaviors and neuroinflammatory in streptozotocin-induced diabetic mice.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Depression; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Hindlimb Suspension; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Male; Mice; Prefrontal Cortex; Streptozocin; Tumor Necrosis Factor-alpha | 2020 |
Atorvastatin attenuates obese-induced kidney injury and impaired renal organic anion transporter 3 function through inhibition of oxidative stress and inflammation.
Topics: Acute Kidney Injury; Animals; Antioxidants; Atorvastatin; Diet, High-Fat; Humans; Inflammation; Insulin; Insulin Resistance; Kidney; Lipid Metabolism; Obesity; Organic Anion Transporters, Sodium-Independent; Oxidative Stress; Rats; Rats, Wistar | 2020 |
Atorvastatin Reduces
Topics: Animals; Arteriovenous Shunt, Surgical; Atorvastatin; Carotid Artery, Internal; Collagen; Female; Fibrin; Fibrosis; Hemorheology; Inflammation; Jugular Veins; Macrophages; Male; Mice; Mice, Inbred C57BL; Molecular Imaging; Nanoparticles; Random Allocation; RNA, Messenger; Thrombosis; Transcription, Genetic; Vascular Access Devices; Vascular Patency | 2020 |
Chitosan-Coated PLGA Nanoparticles for Enhanced Ocular Anti-Inflammatory Efficacy of Atorvastatin Calcium.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Biocompatible Materials; Biological Availability; Chitosan; Drug Carriers; Drug Delivery Systems; Eye Diseases; Gels; Inflammation; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer; Rabbits | 2020 |
Atorvastatin has therapeutic potential for the fatty liver-induced memory dysfunction in rats, likely via its antioxidant and anti-inflammatory properties.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Atorvastatin; Brain; Fatty Liver; Inflammation; Male; Memory Disorders; Oxidative Stress; Rats; Rats, Sprague-Dawley | 2020 |
Effective atherosclerotic plaque inflammation inhibition with targeted drug delivery by hyaluronan conjugated atorvastatin nanoparticles.
Topics: Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atorvastatin; Drug Delivery Systems; Hyaluronan Receptors; Hyaluronic Acid; Inflammation; Macrophages; Mice; Mice, Knockout; Nanoparticles; Plaque, Atherosclerotic; RAW 264.7 Cells | 2020 |
Variability in blood lipids affects the neutrophil to lymphocyte ratio in patients undergoing elective percutaneous coronary intervention: a retrospective study.
Topics: Aged; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipid Metabolism; Lipids; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Risk Factors | 2020 |
Supplementation of pyrroloquinoline quinone with atorvastatin augments mitochondrial biogenesis and attenuates low grade inflammation in obese rats.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Blood Glucose; Cytokines; Disease Models, Animal; Drug Therapy, Combination; Gene Expression Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Lipids; Liver; Male; Mitochondria, Liver; Obesity; Organelle Biogenesis; PQQ Cofactor; Rats, Sprague-Dawley | 2020 |
Combination of Dichloroacetate and Atorvastatin Regulates Excessive Proliferation and Oxidative Stress in Pulmonary Arterial Hypertension Development via p38 Signaling.
Topics: Animals; Apoptosis; Atorvastatin; Cardiomegaly; Cell Proliferation; Cell Survival; Dichloroacetic Acid; Endoplasmic Reticulum Stress; Hemodynamics; Inflammation; Macrophages; Male; Mitochondria; Models, Biological; Monocrotaline; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Pulmonary Arterial Hypertension; Rats, Sprague-Dawley; Signal Transduction | 2020 |
The effects of melatonin against atherosclerosis-induced endothelial dysfunction and inflammation in hypercholesterolemic rats.
Topics: Animals; Atherosclerosis; Atorvastatin; Hypercholesterolemia; Hyperlipidemias; Inflammation; Melatonin; Nicotinamide Phosphoribosyltransferase; Nitric Oxide; Rats | 2023 |
Effect of atorvastatin on AGEs-induced injury of cerebral cortex via inhibiting NADPH oxidase -NF-κB pathway in ApoE
Topics: Amyloid beta-Peptides; Animals; Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Cerebral Cortex; Diet, High-Fat; Gene Expression Regulation; Glycation End Products, Advanced; Immunohistochemistry; Inflammation; Male; Mice; Mice, Knockout; NADPH Oxidases; Neurons; Oxidative Stress; Receptor for Advanced Glycation End Products; Signal Transduction; Thiazoles; Transcription Factor RelA | 2020 |
Inhibitors of 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase (Statins) Suppress Differentiation and Reduce LPS/IFNγ-Induced Cytokine Production in Human Monocyte/Macrophage Culture.
Topics: Apoptosis; Atorvastatin; Caspase 3; Cell Differentiation; Cell Proliferation; Cells, Cultured; Cytokines; Flow Cytometry; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interferon-gamma; Leukocytes, Mononuclear; Lipopolysaccharides; Macrophages; Monocytes; RNA, Messenger; Rosuvastatin Calcium | 2020 |
Western and heart healthy dietary patterns differentially affect the expression of genes associated with lipid metabolism, interferon signaling and inflammation in the jejunum of Ossabaw pigs.
Topics: Animals; Atherosclerosis; Atorvastatin; Cardiometabolic Risk Factors; Coronary Artery Disease; Delta-5 Fatty Acid Desaturase; Diet, Healthy; Diet, Western; Feeding Behavior; Female; Gene Expression; Heart; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interferons; Intestinal Mucosa; Jejunum; Lipid Metabolism; Male; Swine; Tumor Necrosis Factor-alpha | 2021 |
The combination of atorvastatin with silymarin enhances hypolipidemic, antioxidant and anti-inflammatory effects in a rat model of metabolic syndrome.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Atorvastatin; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, Combination; Hypercholesterolemia; Hyperlipidemias; Inflammation; Male; Metabolic Syndrome; Oxidative Stress; Rats; Silymarin; Triglycerides | 2021 |
Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease.
Topics: Aged; Anti-Inflammatory Agents; Aorta; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Female; Fluorodeoxyglucose F18; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Plaque, Atherosclerotic; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Renal Insufficiency, Chronic; Risk Factors | 2021 |
Atorvastatin protects against contrast-induced acute kidney injury via upregulation of endogenous hydrogen sulfide.
Topics: Acute Kidney Injury; Animals; Apoptosis; Atorvastatin; Contrast Media; Cystathionine beta-Synthase; Cystathionine gamma-Lyase; Disease Models, Animal; Hydrogen Sulfide; Inflammation; Kidney; Male; Oxidative Stress; Protective Agents; Rats; Rats, Sprague-Dawley; Sulfides; Up-Regulation | 2020 |
The Effects of Atorvastatin on Global Cerebral Ischemia-Induced Neuronal Death.
Topics: Animals; Atorvastatin; Behavior, Animal; Brain Ischemia; Cognition Disorders; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Neurons; Neuroprotective Agents; Oxidative Stress; Rats; Rats, Sprague-Dawley | 2021 |
Effects of atorvastatin and diet interventions on atherosclerotic plaque inflammation and [
Topics: Animal Feed; Animals; Aortic Diseases; Apolipoprotein B-100; Atherosclerosis; Atorvastatin; Diet, Fat-Restricted; Diet, High-Fat; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Genetic Predisposition to Disease; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Mice, Knockout; Phenotype; Plaque, Atherosclerotic; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Receptors, LDL; Time Factors | 2017 |
13-Series resolvins mediate the leukocyte-platelet actions of atorvastatin and pravastatin in inflammatory arthritis.
Topics: Animals; Anticholesteremic Agents; Arthritis; Atorvastatin; Docosahexaenoic Acids; Inflammation; Leukocytes; Male; Mice; Mice, Inbred C57BL; Pravastatin | 2017 |
LINC00341 exerts an anti-inflammatory effect on endothelial cells by repressing VCAM1.
Topics: Atorvastatin; Cell Adhesion; Gene Expression Regulation; Gene Regulatory Networks; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Monocytes; Polycomb Repressive Complex 2; RNA, Long Noncoding; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2017 |
Atorvastatin Promotes Phagocytosis and Attenuates Pro-Inflammatory Response in Human Retinal Pigment Epithelial Cells.
Topics: Atorvastatin; Cell Line; Cholesterol; Epithelial Cells; Humans; Inflammation; Interleukin-6; Interleukin-8; Lipoproteins, LDL; Macular Degeneration; Phagocytosis; Retinal Pigment Epithelium | 2017 |
Statins Reduce Lipopolysaccharide-Induced Cytokine and Inflammatory Mediator Release in an In Vitro Model of Microglial-Like Cells.
Topics: Anti-Inflammatory Agents; Antioxidants; Atorvastatin; Cell Proliferation; Chronic Disease; Dinoprostone; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Inflammation; Interleukin-1beta; Lipids; Lipopolysaccharides; Microglia; Monocytes; Nitric Oxide; Pravastatin; Quinolines; Reactive Oxygen Species; Rosuvastatin Calcium; Simvastatin; THP-1 Cells; Tumor Necrosis Factor-alpha | 2017 |
[Role of atorvastatin in improving the inflammation-induced adipokine imbalance in mice with acute myocardial infarction].
Topics: Adipokines; Adiponectin; Animals; Anti-Inflammatory Agents; Atorvastatin; C-Reactive Protein; Gene Expression; Inflammation; Mice; Mice, Inbred C57BL; Myocardial Infarction; Resistin | 2017 |
Anti-atherosclerotic effect of Longxuetongluo Capsule in high cholesterol diet induced atherosclerosis model rats.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Diet, High-Fat; Disease Models, Animal; Drugs, Chinese Herbal; Hypercholesterolemia; Inflammation; Lipid Metabolism; Lipids; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; NF-kappa B; Plaque, Atherosclerotic; Rats; Rats, Sprague-Dawley | 2018 |
Galectin-3 in patients with coronary heart disease and atrial fibrillation.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Atrial Fibrillation; Blood Proteins; Catheter Ablation; Coronary Disease; Female; Fibrosis; Galectin 3; Galectins; Humans; Inflammation; Male; Middle Aged; Myocardial Infarction; Severity of Illness Index; Stroke Volume | 2018 |
Atorvastatin Reduces Plasma Inflammatory and Oxidant Biomarkers in Patients With Risk of Atherosclerotic Cardiovascular Disease.
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; C-Reactive Protein; Dose-Response Relationship, Drug; Endothelin-1; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Oxidants; Oxidative Stress; Peroxidase; Prospective Studies; Risk Factors; Superoxide Dismutase | 2018 |
Comparison of lipid profiles and inflammation in pre- and post-menopausal women with cerebral infarction and the role of atorvastatin in such populations.
Topics: Adult; Atorvastatin; Cerebral Infarction; Cholesterol; Cytokines; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Menopause; Middle Aged; Triglycerides | 2018 |
Atorvastatin Treatment Modulates the Gut Microbiota of the Hypercholesterolemic Patients.
Topics: Adolescent; Adult; Anticholesteremic Agents; Atorvastatin; Bacteria; Cholesterol; Female; Gastrointestinal Microbiome; Humans; Hypercholesterolemia; Inflammation; Lipid Metabolism; Male; Middle Aged; RNA, Ribosomal, 16S; Young Adult | 2018 |
Atorvastatin might resist tobacco smoking-induced endothelial inflammation through the inhibition of NF-κB signal pathway.
Topics: Atorvastatin; Cells, Cultured; Complex Mixtures; E-Selectin; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Inflammation; NF-kappa B; Signal Transduction; Tobacco Smoking; Vascular Cell Adhesion Molecule-1 | 2019 |
Atorvastatin dose-dependently promotes mouse lung repair after emphysema induced by elastase.
Topics: Animals; Atorvastatin; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Dose-Response Relationship, Drug; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Leukocytes; Macrophages; Male; Mice; Mice, Inbred C57BL; Neutrophils; Oxidative Stress; Pancreatic Elastase; Pulmonary Emphysema; Swine; Time Factors | 2018 |
The Ossabaw Pig Is a Suitable Translational Model to Evaluate Dietary Patterns and Coronary Artery Disease Risk.
Topics: Animals; Atherosclerosis; Atorvastatin; Cholesterol; Coronary Artery Disease; Diet, Healthy; Diet, Western; Dietary Fats; Disease Models, Animal; Dyslipidemias; Energy Intake; Fatty Acids; Feeding Behavior; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Risk Factors; Swine; Triglycerides | 2018 |
Paradoxical effects of atorvastatin in isoproterenol-induced cardiotoxicity in rats: Role of oxidative stress and inflammation.
Topics: Animals; Antioxidants; Atorvastatin; Biomarkers; Cardiotonic Agents; Cardiotoxicity; Heart; Inflammation; Isoproterenol; Male; Myocardial Infarction; Myocardium; Oxidative Stress; Rats; Rats, Wistar | 2018 |
[Protective effects of combined use of atorvastatin and low molecular weight heparin on the inflammatory reaction and pulmonary functions in rats with sepsis].
Topics: Animals; Atorvastatin; Cytokines; Disease Models, Animal; Heparin, Low-Molecular-Weight; HMGB1 Protein; Inflammation; Interleukin-1beta; Interleukin-6; Lung; Male; Random Allocation; Rats; Rats, Sprague-Dawley; Sepsis; Tumor Necrosis Factor-alpha | 2016 |
Statin treatment reduces matrix degradation capacity of proinflammatory polarized macrophages.
Topics: Anti-Inflammatory Agents; Atorvastatin; Cell Plasticity; Cells, Cultured; Extracellular Matrix; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Macrophages; Matrix Metalloproteinase 14; Phenotype; Proteolysis; Pseudopodia; Receptors, Urokinase Plasminogen Activator | 2018 |
Effect of Combined Use of Astragaloside IV (AsIV) and Atorvastatin (AV) on Expression of PPAR-γ and Inflammation-Associated Cytokines in Atherosclerosis Rats.
Topics: Animals; Atherosclerosis; Atorvastatin; China; Cytokines; Disease Models, Animal; Drug Therapy, Combination; Inflammation; Interleukin-18; Interleukin-6; Lipoproteins, HDL; Lipoproteins, LDL; Male; PPAR gamma; Rats; Rats, Sprague-Dawley; Saponins; Signal Transduction; Triterpenes; Tumor Necrosis Factor-alpha | 2018 |
Statin therapy modulates thickness and inflammatory profile of human epicardial adipose tissue.
Topics: Adipose Tissue; Aged; Aortic Valve; Aortic Valve Stenosis; Atorvastatin; Biopsy; Calcinosis; Coronary Artery Disease; Cytokines; Echocardiography; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Pericardium; Retrospective Studies | 2019 |
Using zebrafish larval models to study brain injury, locomotor and neuroinflammatory outcomes following intracerebral haemorrhage.
Topics: Animals; Atorvastatin; Brain; Brain Injuries; Cerebral Hemorrhage; Disease Models, Animal; Immunity, Innate; Inflammation; Larva; Locomotion; Macrophage Activation; Mutation; Phagocytosis; Phenotype; Zebrafish | 2018 |
Fufang-Zhenzhu-Tiaozhi Capsule reduces restenosis via the downregulation of NF-kappaB and inflammatory factors in rabbits.
Topics: Animals; Aorta, Abdominal; Atherosclerosis; Atorvastatin; C-Reactive Protein; Chemokine CCL2; Coronary Restenosis; Diet, High-Fat; Disease Models, Animal; Drugs, Chinese Herbal; Endothelium; Gene Expression Regulation; Humans; Inflammation; Interleukin-1; Interleukin-12; Interleukin-6; Interleukin-8; NF-kappa B; Rabbits; Tumor Necrosis Factor-alpha | 2018 |
Effects of atorvastatin and/or probucol on recovery of atherosclerosis in high-fat-diet-fed apolipoprotein E-deficient mice.
Topics: Animals; Antioxidants; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cholesterol; Cytokines; Diet, High-Fat; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Inflammation; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Probucol | 2019 |
Effect of atorvastatin on oxidative stress and inflammation markers in myxomatous mitral valve disease in dogs: A comparison of subclinical and clinical stages.
Topics: Animals; Asymptomatic Diseases; Atorvastatin; Dog Diseases; Dogs; Echocardiography; Female; Hemodynamics; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Mitral Valve Prolapse; Natriuretic Peptide, Brain; Oxidative Stress; Peptide Fragments; Tumor Necrosis Factor-alpha | 2019 |
Synergistic effects of liposomes encapsulating atorvastatin calcium and curcumin and targeting dysfunctional endothelial cells in reducing atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cell Death; Cell Survival; Chemokine CCL2; Curcumin; Drug Synergism; E-Selectin; Endothelial Cells; Humans; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-6; Ligands; Lipids; Liposomes; Mice, Knockout; Particle Size; Static Electricity | 2019 |
Moderate- and Low-Dose of Atorvastatin Alleviate Cognition Impairment Induced by High-Fat Diet via Sirt1 Activation.
Topics: Animals; Antioxidants; Atorvastatin; Body Weight; Cognition; Cognitive Dysfunction; Diet, High-Fat; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Mice, Inbred C57BL; Obesity; Oxidative Stress; Sirtuin 1 | 2019 |
Statins and myocardial infarction: from secondary 'prevention' to early 'treatment'.
Topics: Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Myocardial Infarction; Percutaneous Coronary Intervention; Secondary Prevention; ST Elevation Myocardial Infarction | 2019 |
Heme oxygenase-1-Dependent anti-inflammatory effects of atorvastatin in zymosan-injected subcutaneous air pouch in mice.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Cell Movement; Female; Gene Expression Regulation, Enzymologic; Heme Oxygenase-1; Inflammation; Macrophages; Membrane Proteins; Metalloporphyrins; Mice; Monocytes; Neutrophils; Protoporphyrins; Zymosan | 2019 |
Evaluation of the Anti-Inflammatory Activities of Diclofenac Sodium, Prednisolone and Atorvastatin in Combination with Ascorbic Acid.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Ascorbic Acid; Atorvastatin; Diclofenac; Disease Models, Animal; Drug Combinations; Drug Dosage Calculations; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Prednisolone; Rats; Treatment Outcome | 2020 |
Dietary patterns influence epicardial adipose tissue fatty acid composition and inflammatory gene expression in the Ossabaw pig.
Topics: Adiponectin; Adipose Tissue; Animals; Arachidonate 5-Lipoxygenase; Atorvastatin; Coronary Artery Disease; Cyclooxygenase 2; Diet; Dietary Fats; Fatty Acids; Fatty Acids, Unsaturated; Female; Gene Expression Regulation; Inflammation; Lipids; Male; Pericardium; PPAR gamma; Receptors, G-Protein-Coupled; Signal Transduction; Swine; Toll-Like Receptor 2 | 2019 |
Ginkgolide B Mediated Alleviation of Inflammatory Cascades and Altered Lipid Metabolism in HUVECs via Targeting PCSK-9 Expression and Functionality.
Topics: Atorvastatin; Cell Adhesion Molecules; Cholesterol; Cytokines; Down-Regulation; Ginkgolides; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Inflammation Mediators; Lactones; Lipid Metabolism; Lipoproteins, LDL; NADPH Oxidase 4; Proprotein Convertase 9; Reactive Oxygen Species; Receptors, LDL; Scavenger Receptors, Class E; Sterol Regulatory Element Binding Protein 2 | 2019 |
Promising role of ferulic acid, atorvastatin and their combination in ameliorating high fat diet-induced stress in mice.
Topics: Animals; Antioxidants; Atorvastatin; Coumaric Acids; Diet, High-Fat; Drug Therapy, Combination; Free Radical Scavengers; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Interleukin-6; Lipid Peroxidation; Liver; Male; Mice; NF-kappa B; Oxidative Stress; Pyrroles; Reactive Oxygen Species; Signal Transduction; Tumor Necrosis Factor-alpha; Weight Gain | 2013 |
Monitoring plaque inflammation in atherosclerotic rabbits with an iron oxide (P904) and (18)F-FDG using a combined PET/MR scanner.
Topics: Animals; Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Atorvastatin; Contrast Media; Dextrans; Disease Models, Animal; Disease Progression; Fluorodeoxyglucose F18; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Magnetic Resonance Imaging; Magnetite Nanoparticles; Plaque, Atherosclerotic; Positron-Emission Tomography; Predictive Value of Tests; Pyrroles; Rabbits; Radiography; Radiopharmaceuticals; Time Factors | 2013 |
[Role of inflammation in etiology of atrial fibrillation--is lone arrhythmia really alone].
Topics: Atorvastatin; Atrial Fibrillation; C-Reactive Protein; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Pyrroles; Recurrence | 2012 |
In vivo evaluation of atherosclerotic plaque inflammation and of anti-inflammatory effects of statins by 18F-fluorodeoxyglucose positron emission tomography.
Topics: Aorta, Thoracic; Atherosclerosis; Atorvastatin; Carotid Arteries; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Plaque, Atherosclerotic; Pyrroles; Radionuclide Imaging | 2013 |
Atorvastatin enhance efficacy of mesenchymal stem cells treatment for swine myocardial infarction via activation of nitric oxide synthase.
Topics: Animals; Apoptosis; Atorvastatin; C-Reactive Protein; Disease Models, Animal; Enzyme Activation; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mesenchymal Stem Cell Transplantation; Myocardial Infarction; Myocardium; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pyrroles; Swine; Tomography, Emission-Computed, Single-Photon; Ventricular Function, Left | 2013 |
Redox markers and inflammation are differentially affected by atorvastatin, pravastatin or simvastatin administered before endotoxin-induced acute lung injury.
Topics: Animals; Atorvastatin; Biomarkers; Endotoxins; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lung Injury; Male; Mice; Mice, Inbred C57BL; Oxidation-Reduction; Pravastatin; Pyrroles; Simvastatin | 2013 |
Atorvastatin favorably modulates proinflammatory cytokine profile in patients following deep vein thrombosis.
Topics: Atorvastatin; C-Reactive Protein; Cytokines; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukins; P-Selectin; Pyrroles; Venous Thromboembolism | 2013 |
Improved neurocognitive functions correlate with reduced inflammatory burden in atrial fibrillation patients treated with intensive cholesterol lowering therapy.
Topics: Aged; Amygdala; Anticholesteremic Agents; Atorvastatin; Atrial Fibrillation; Azetidines; Brain; Cognition; Electrocardiography; Executive Function; Ezetimibe; Female; Heptanoic Acids; Hippocampus; Humans; Image Processing, Computer-Assisted; Inflammation; Magnetic Resonance Imaging; Male; Memory; Neuroimaging; Neuropsychological Tests; Psychomotor Performance; Pyrroles; Reaction Time; Vocabulary | 2013 |
Atorvastatin safety in Kawasaki disease patients with coronary artery aneurysms.
Topics: Administration, Oral; Anthropometry; Anti-Inflammatory Agents; Atorvastatin; Canada; Child; Child Development; Cholesterol; Coronary Aneurysm; Coronary Vessels; Dose-Response Relationship, Drug; Drug Monitoring; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Liver Function Tests; Male; Medical Records, Problem-Oriented; Mucocutaneous Lymph Node Syndrome; Pyrroles; Retrospective Studies | 2014 |
Combination therapy with atorvastatin and amlodipine suppresses angiotensin II-induced aortic aneurysm formation.
Topics: Amlodipine; Angiotensin II; Animals; Aortic Aneurysm, Abdominal; Apoptosis; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Disease Models, Animal; Drug Therapy, Combination; Enzyme Activation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Matrix Metalloproteinases; Mice; Mice, Knockout; Pyrroles; rho-Associated Kinases | 2013 |
Improvement of the efficacy of dihydroartemisinin with atorvastatin in an experimental cerebral malaria murine model.
Topics: Animals; Anti-Inflammatory Agents; Antimalarials; Artemisinins; Atorvastatin; Biomarkers; Disease Models, Animal; Drug Therapy, Combination; Female; Heptanoic Acids; Inflammation; Malaria, Cerebral; Mice; Mice, Inbred C57BL; Pyrroles; Survival Analysis; Treatment Outcome | 2013 |
Comment on atorvastatin safety in kawasaki disease patients with coronary artery aneurysms.
Topics: Atorvastatin; Child Development; Coronary Aneurysm; Coronary Vessels; Female; Heptanoic Acids; Humans; Inflammation; Male; Mucocutaneous Lymph Node Syndrome; Pyrroles | 2014 |
Author reply to comment on "atorvastatin safety in Kawasaki disease patients with coronary artery aneurysms".
Topics: Atorvastatin; Child Development; Coronary Aneurysm; Coronary Vessels; Female; Heptanoic Acids; Humans; Inflammation; Male; Mucocutaneous Lymph Node Syndrome; Pyrroles | 2014 |
Are statins 'IDEAL' for non-alcoholic fatty liver disease?
Topics: Atorvastatin; Carcinoma, Hepatocellular; Cardiovascular Diseases; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Liver; Liver Neoplasms; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Triglycerides | 2014 |
Atorvastatin decreases bone loss, inflammation and oxidative stress in experimental periodontitis.
Topics: Alveolar Bone Loss; Animals; Atorvastatin; Heptanoic Acids; Inflammation; Male; Oxidative Stress; Periodontitis; Pyrroles; Rats; Rats, Wistar | 2013 |
Inflammatory stress induces statin resistance by disrupting 3-hydroxy-3-methylglutaryl-CoA reductase feedback regulation.
Topics: Animals; Apolipoproteins E; Atorvastatin; CD36 Antigens; Cholesterol; Cholesterol, Dietary; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance; Feedback, Physiological; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Inflammation Mediators; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pyrroles; RNA Interference; Scavenger Receptors, Class A; Stress, Physiological; Time Factors; Transfection | 2014 |
10-Dehydrogingerdione raises HDL-cholesterol through a CETP inhibition and wards off oxidation and inflammation in dyslipidemic rabbits.
Topics: Animals; Atorvastatin; C-Reactive Protein; Cell Proliferation; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Diet, Atherogenic; Disease Models, Animal; Dyslipidemias; Guaiacol; Heptanoic Acids; Inflammation; Male; Mass Spectrometry; Oxygen; Pyrroles; Rabbits; Risk Factors | 2013 |
Effects of single-dose atorvastatin on interleukin-6, interferon gamma, and myocardial no-reflow in a rabbit model of acute myocardial infarction and reperfusion.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Coronary Occlusion; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Immunohistochemistry; Inflammation; Interferon-gamma; Interleukin-6; Ligation; Male; Multivariate Analysis; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Necrosis; No-Reflow Phenomenon; Pyrroles; Rabbits; Random Allocation | 2014 |
Effects of atorvastatin on the inflammation regulation and elimination of subdural hematoma in rats.
Topics: Analysis of Variance; Animals; Atorvastatin; Blood Cell Count; Brain; Cytokines; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Hematoma, Subdural; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Processing, Computer-Assisted; Inflammation; Lipids; Magnetic Resonance Imaging; Male; Neurologic Examination; Pyrroles; Rats; Rats, Wistar; Time Factors | 2014 |
Statin-induced impairment of monocyte migration is gender-related.
Topics: Atherosclerosis; Atorvastatin; Cell Movement; Female; Healthy Volunteers; Heptanoic Acids; Humans; Inflammation; Lipopolysaccharides; Male; Monocytes; Pyrroles; Sex Characteristics; Simvastatin; Tumor Necrosis Factor-alpha | 2014 |
Effects of single pill-based combination therapy of amlodipine and atorvastatin on within-visit blood pressure variability and parameters of renal and vascular function in hypertensive patients with chronic kidney disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Capsules; Drug Therapy, Combination; Female; Glucose; Heptanoic Acids; Humans; Hypertension; Inflammation; Kidney; Kidney Function Tests; Lipid Metabolism; Male; Multivariate Analysis; Oxidative Stress; Pyrroles; Regression Analysis; Renal Insufficiency, Chronic | 2014 |
Atorvastatin improves survival of implanted stem cells in a rat model of renal ischemia-reperfusion injury.
Topics: Acute Kidney Injury; Animals; Atorvastatin; Graft Survival; Heptanoic Acids; HMGB1 Protein; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Innate; Inflammation; Kidney; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Oxidative Stress; Pyrroles; Rats; Reperfusion Injury; Toll-Like Receptor 4 | 2014 |
Inflammatory stress reduces the effectiveness of statins in the kidney by disrupting HMGCoA reductase feedback regulation.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apolipoproteins E; Atorvastatin; Blotting, Western; Caseins; CD36 Antigens; Cells, Cultured; Cholesterol; Cytokines; Drug Resistance; Feedback, Physiological; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Kidney; Lipopolysaccharides; Male; Mesangial Cells; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sterol Regulatory Element Binding Protein 2; Stress, Physiological; Treatment Outcome; Tumor Necrosis Factor-alpha | 2014 |
Stimulatory interactions between human coronary smooth muscle cells and dendritic cells.
Topics: Animals; Atorvastatin; Cell Adhesion; Cell Adhesion Molecules; Cell Differentiation; Cell Movement; Cellular Microenvironment; Coculture Techniques; Coronary Vessels; Cytokines; Dendritic Cells; Heptanoic Acids; Humans; Immunophenotyping; Inflammation; Male; Myocytes, Smooth Muscle; Phenotype; Pyrroles; Rats, Wistar; Rosiglitazone; Solubility; Thiazolidinediones | 2014 |
Short-term intensive atorvastatin therapy improves endothelial function partly via attenuating perivascular adipose tissue inflammation through 5-lipoxygenase pathway in hyperlipidemic rabbits.
Topics: Adipose Tissue; Animals; Arachidonate 5-Lipoxygenase; Atorvastatin; Heptanoic Acids; Hyperlipidemias; Inflammation; Lipid Metabolism; Male; Pyrroles; Rabbits | 2014 |
99mTc-cAbVCAM1-5 imaging is a sensitive and reproducible tool for the detection of inflamed atherosclerotic lesions in mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Female; Heptanoic Acids; Humans; Immunoglobulin Fragments; Immunohistochemistry; Inflammation; Mice; Multimodal Imaging; Pyrroles; Reference Values; Reproducibility of Results; Technetium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Vascular Cell Adhesion Molecule-1 | 2014 |
Evaluation of the Anti-inflammatory Activity of Atorvastatin and its Effect on Alveolar Diameter in a Model of Elastase-induced Emphysema in Rats.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Disease Models, Animal; Inflammation; Leukocytes; Male; Nitric Oxide; Pancreatic Elastase; Pulmonary Alveoli; Pulmonary Emphysema; Rats; Rats, Wistar | 2015 |
Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease.
Topics: Aged; Atherosclerosis; Atorvastatin; Blood Pressure; Coronary Angiography; Coronary Artery Disease; Cross-Sectional Studies; Female; Fluorobenzenes; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Heptanoic Acids; Humans; Inflammation; Interleukin-10; Lipids; Lipoproteins, HDL; Macrophage Colony-Stimulating Factor; Male; Middle Aged; Monocytes; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2014 |
[Effect of atorvastatin on pro-inflammatory status (in vivo and in vitro) in patients with essential hypertension and metabolic syndrome].
Topics: Anticholesteremic Agents; Atorvastatin; Cytokines; Dose-Response Relationship, Drug; Drug Monitoring; Essential Hypertension; Female; Heptanoic Acids; Humans; Hypertension; Inflammation; Leukocytes, Mononuclear; Male; Metabolic Syndrome; Middle Aged; Patient Acuity; Prospective Studies; Pyrroles; Reactive Oxygen Species; Severity of Illness Index; Treatment Outcome | 2014 |
Role of inflammation in the initiation and maintenance of atrial fibrillation and the protective effect of atorvastatin in a goat model of aseptic pericarditis.
Topics: Animals; Atorvastatin; Atrial Fibrillation; Cardiac Surgical Procedures; Cytokines; Disease Models, Animal; Goats; Heart Atria; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Male; Pericarditis; Pyrroles | 2015 |
Ameliorative potential of omega 3 fatty acids and HMG-CoA reductase inhibitors on experimentally-induced non-alcoholic steatohepatitis.
Topics: Animals; Atorvastatin; Body Weight; Cytokines; Diet, High-Fat; Disease Models, Animal; Fatty Acids, Omega-3; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Insulin Resistance; Lipids; Liver; Male; Non-alcoholic Fatty Liver Disease; Rats, Wistar; Sucrose | 2015 |
The role of statins in inflammatory vasculitides.
Topics: Adaptive Immunity; Adolescent; Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Atorvastatin; Behcet Syndrome; Child; Child, Preschool; Clinical Trials as Topic; Drug Repositioning; Humans; Immunity, Innate; Infant; Inflammation; Mucocutaneous Lymph Node Syndrome | 2015 |
The effects of atorvastatin on antioxidant/antiinflammatory properties of HDLs in hypercholesterolemics.
Topics: Adult; Anticholesteremic Agents; Arginine; Atorvastatin; Drug Monitoring; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Lipoproteins, HDL; Male; Malondialdehyde; Middle Aged; Nitric Oxide; Oxidative Stress; Pyrroles; Treatment Outcome | 2015 |
Acute perioperative-stress-induced increase of atherosclerotic plaque volume and vulnerability to rupture in apolipoprotein-E-deficient mice is amenable to statin treatment and IL-6 inhibition.
Topics: Animals; Apolipoproteins E; Atorvastatin; Cholesterol; Disease Models, Animal; Female; Hemodynamics; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Laparotomy; Lipoproteins; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Perioperative Period; Plaque, Atherosclerotic; Rupture; Serum Amyloid A Protein; Signal Transduction | 2015 |
Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits.
Topics: Animals; Aorta; Atherosclerosis; Atorvastatin; Biomarkers; Cilostazol; Drug Therapy, Combination; Hypercholesterolemia; Inflammation; Lipids; Male; Oxidation-Reduction; Oxidative Stress; Probucol; Rabbits; Tetrazoles | 2015 |
[Pleiotropic effects of atorvastatin in rheumatoid arthritis patients with no history of cardiovascular diseases].
Topics: Adult; Anticholesteremic Agents; Arthritis, Rheumatoid; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Humans; Inflammation; Interleukin-6; Lipid Metabolism; Matrix Metalloproteinase 3; Middle Aged; Patient Acuity; Rheumatoid Factor; Treatment Outcome; Triglycerides; Tumor Necrosis Factor-alpha | 2015 |
Resolvin Infectious Inflammation by Targeting the Host Response.
Topics: Animals; Atorvastatin; Cells, Cultured; Disease Models, Animal; Docosahexaenoic Acids; Endothelial Cells; Escherichia coli Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mice; Neutrophils; Phagocytosis; Sepsis | 2015 |
Inflammation Activation Contributes to Adipokine Imbalance in Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adipokines; Adiponectin; Animals; Atorvastatin; Blotting, Western; C-Reactive Protein; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Mice; Mice, Inbred C57BL; Middle Aged; Myocardial Infarction; Resistin | 2016 |
Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin.
Topics: Animals; Aorta; Atherosclerosis; Atorvastatin; Cholesterol; Cholesterol, LDL; E-Selectin; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Mice; Mice, Knockout, ApoE; Oligonucleotide Array Sequence Analysis; Serum Amyloid A Protein; Treatment Outcome; Vascular Cell Adhesion Molecule-1 | 2016 |
The Effects and Mechanism of Atorvastatin on Pulmonary Hypertension Due to Left Heart Disease.
Topics: Animals; Aorta; Apoptosis; Arterioles; Atorvastatin; Cell Proliferation; Heart Diseases; Heart Failure; Hemodynamics; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Inflammation; Lung; Macrophages; Male; Myocardial Ischemia; Neutrophils; Rats; Rats, Sprague-Dawley | 2016 |
Amlodipine and atorvastatin improve ventricular hypertrophy and diastolic function via inhibiting TNF-α, IL-1β and NF-κB inflammatory cytokine networks in elderly spontaneously hypertensive rats.
Topics: Aging; Amlodipine; Animals; Atorvastatin; C-Reactive Protein; Cardiomegaly; Diastole; Heart Ventricles; I-kappa B Proteins; Inflammation; Interleukin-1beta; Male; Myocardium; NF-kappa B; Rats, Inbred SHR; Rats, Inbred WKY; Tumor Necrosis Factor-alpha | 2016 |
Inflammatory Stress Sensitizes the Liver to Atorvastatin-Induced Injury in ApoE-/- Mice.
Topics: Animals; Apolipoproteins E; Atorvastatin; Caseins; Catalase; Chemical and Drug Induced Liver Injury; Gene Expression Regulation; Inflammation; Liver; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Mice, Knockout; NF-E2-Related Factor 2; Reactive Oxygen Species; RNA, Messenger; Superoxide Dismutase | 2016 |
Association of Long-Term Atorvastatin with Escalated Stroke-Induced Neuroinflammation in Rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; bcl-2-Associated X Protein; Caspase 9; Infarction, Middle Cerebral Artery; Inflammation; Interleukin-6; Male; Neurons; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha | 2017 |
Involvement of peroxisome proliferator activated receptor-γ in the anti-inflammatory effects of atorvastatin in oxygen-glucose deprivation/reperfusion-stimulated RAW264.7 murine macrophages.
Topics: Animals; Atorvastatin; Disease Models, Animal; Gene Expression Regulation; Gene Knockdown Techniques; Glucose; Humans; Inflammation; Interferon-gamma; Lectins, C-Type; Mannose Receptor; Mannose-Binding Lectins; Mice; Nitric Oxide Synthase Type II; Oxygen; PPAR gamma; RAW 264.7 Cells; Receptors, Cell Surface; Reperfusion Injury; Tumor Necrosis Factor-alpha | 2016 |
Atorvastatin, Losartan and Captopril Lead to Upregulation of TGF-β, and Downregulation of IL-6 in Coronary Artery Disease and Hypertension.
Topics: Antihypertensive Agents; Atorvastatin; Captopril; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Inflammation; Interleukin-6; Interleukin-8; Iran; Losartan; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Up-Regulation | 2016 |
Statin inhibits kainic acid-induced seizure and associated inflammation and hippocampal cell death.
Topics: Animals; Atorvastatin; Cell Death; Disease Models, Animal; Dose-Response Relationship, Drug; Ectodysplasins; Heptanoic Acids; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Inflammation; Interleukin-1beta; Kainic Acid; Male; Nitric Oxide Synthase Type II; Pyrroles; Rats; Rats, Sprague-Dawley; Seizures; Tumor Necrosis Factor-alpha | 2008 |
Polycystic ovary syndrome, inflammation, and statins: do we have the right target?
Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Polycystic Ovary Syndrome; Pregnancy; Pyrroles; Testosterone | 2009 |
Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure.
Topics: Atorvastatin; Biomarkers; Case-Control Studies; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunoenzyme Techniques; Inflammation; Interferon-gamma; Interleukin-10; Interleukin-12; Interleukin-18; Interleukin-4; Male; Middle Aged; Pyrroles; Th1 Cells; Th2 Cells | 2009 |
Iron oxide magnetic resonance imaging for atherosclerosis therapeutic evaluation: still "rusty?".
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; Carotid Stenosis; Ferric Compounds; Heptanoic Acids; Humans; Inflammation; Macrophages; Nanoparticles; Pyrroles | 2009 |
[Effect of atorvastatin on inflammatory infiltration in the lung of rabbits with hypercholesterolemia].
Topics: Animals; Atorvastatin; Bronchoalveolar Lavage; Heptanoic Acids; Hypercholesterolemia; Inflammation; Lung; Macrophages, Alveolar; Male; NF-kappa B; Pyrroles; Rabbits; Random Allocation | 2009 |
FDG-PET can distinguish inflamed from non-inflamed plaque in an animal model of atherosclerosis.
Topics: Animals; Aorta; Atherosclerosis; Atorvastatin; Catheterization; Cholesterol, Dietary; Diagnosis, Differential; Disease Models, Animal; Fluorodeoxyglucose F18; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Macrophages; Male; Positron-Emission Tomography; Predictive Value of Tests; Pyrroles; Rabbits; Radiopharmaceuticals | 2010 |
Atorvastatin inhibits inflammatory angiogenesis in mice through down regulation of VEGF, TNF-alpha and TGF-beta1.
Topics: Administration, Oral; Animals; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Macrophages; Male; Mice; Neovascularization, Pathologic; Pyrroles; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2010 |
18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Binding, Competitive; Cells, Cultured; Contrast Media; Disease Models, Animal; Endothelium, Vascular; Feasibility Studies; Fluorodeoxyglucose F18; Graft Rejection; Half-Life; Heart Transplantation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Iopamidol; Ligands; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Peptides; Positron-Emission Tomography; Predictive Value of Tests; Pyrroles; Radiopharmaceuticals; Reproducibility of Results; RNA, Messenger; Tissue Distribution; Tomography, X-Ray Computed; Vascular Cell Adhesion Molecule-1 | 2009 |
Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome.
Topics: Animals; Anticholesteremic Agents; Arterioles; Atorvastatin; Cytokines; Gemfibrozil; Heptanoic Acids; Inflammation; Male; Metabolic Syndrome; Microcirculation; Muscle, Skeletal; Nitric Oxide; Probucol; Pyrroles; Rats; Rats, Zucker; Simvastatin; Time Factors | 2009 |
Atorvastatin ameliorates inflammatory hyperalgesia in rat model of monoarticular arthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Atorvastatin; Diclofenac; Female; Freund's Adjuvant; Heptanoic Acids; Hyperalgesia; Inflammation; Joints; Lower Extremity; Male; Motor Activity; Pyrroles; Rats; Rats, Wistar | 2010 |
Effect of atorvastatin and diet on non-alcoholic fatty liver disease activity score in hyperlipidemic chickens.
Topics: Animals; Atorvastatin; Chickens; Cholesterol; Disease Models, Animal; Fatty Liver; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Male; Pyrroles; Severity of Illness Index; Triglycerides | 2010 |
Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha levels in type 2 diabetes.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; CD36 Antigens; Cells, Cultured; Diabetes Mellitus, Type 2; Down-Regulation; Female; Heptanoic Acids; Humans; Inflammation; Male; Middle Aged; Monocytes; NF-kappaB-Inducing Kinase; Protein Serine-Threonine Kinases; Pyrroles; Tumor Necrosis Factor-alpha | 2010 |
Effects of clopidogrel on vascular proliferation and apoptosis in an atherosclerotic rabbit model.
Topics: Animals; Apoptosis; Atherosclerosis; Atorvastatin; C-Reactive Protein; Catheterization; Clopidogrel; Endothelium, Vascular; Heptanoic Acids; Inflammation; Male; Platelet-Derived Growth Factor; Pyrroles; Rabbits; Random Allocation; Ticlopidine; Tunica Intima | 2010 |
Effect of atorvastatin on haemostasis, fibrinolysis and inflammation in normocholesterolaemic patients with coronary artery disease: a post hoc analysis of data from a prospective, randomized, double-blind study.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Double-Blind Method; Female; Fibrinolysis; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles; Randomized Controlled Trials as Topic; Thrombin | 2010 |
The influence of Sam-Chil-Geun (Panax notoginseng) on the serum lipid levels and inflammations of rats with hyperlipidemia induced by poloxamer-407.
Topics: Animals; Atorvastatin; Cholesterol; Cyclooxygenase 2; Drugs, Chinese Herbal; Heptanoic Acids; Hyperlipidemias; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-1; Lipids; Male; Poloxamer; Pyrroles; Rats; Rats, Wistar; Triglycerides; Tumor Necrosis Factor-alpha | 2010 |
Atorvastatin treatment affects atrial ion currents and their tachycardia-induced remodeling in rabbits.
Topics: Animals; Atorvastatin; Atrial Fibrillation; Female; Heart Atria; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Ion Channels; Oxidative Stress; Patch-Clamp Techniques; Pyrroles; Rabbits; Tachycardia; Time Factors | 2010 |
Matrix metalloproteinase-9 may be a potential therapeutic target in epilepsy.
Topics: Animals; Anti-Bacterial Agents; Atorvastatin; Epilepsy; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Matrix Metalloproteinase 9; Mice; Minocycline; Models, Biological; Neurons; Pyrroles; Rats; Seizures; Treatment Outcome | 2011 |
Effects of immunomodulatory drugs on plasma inflammatory markers in a rabbit model of atherosclerosis.
Topics: Animals; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, LDL; Cyclosporine; Heptanoic Acids; Immunologic Factors; Inflammation; Interferon-gamma; Interleukin-6; Male; Plasma; Pyrroles; Rabbits; Tacrolimus; Triglycerides | 2011 |
[Atorvastatin and oxidized low density lipoprotein antibody. Relationship to age].
Topics: Adult; Age Factors; Aged; Atherosclerosis; Atorvastatin; Autoantibodies; Autoantigens; Blood Glucose; C-Reactive Protein; Creatinine; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipid Peroxidation; Lipids; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Risk Factors; Waist Circumference | 2011 |
Atorvastatin improves survival in septic rats: effect on tissue inflammatory pathway and on insulin signaling.
Topics: Adipose Tissue; Animals; Atorvastatin; Glucose; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Insulin; Interleukin-6; Liver; Male; Muscles; Pyrroles; Rats; Rats, Wistar; Sepsis; Signal Transduction; Tumor Necrosis Factor-alpha | 2010 |
The effect of atorvastatin on mRNA levels of inflammatory genes expression in human peripheral blood lymphocytes by DNA microarray.
Topics: Atorvastatin; Chemokines; Cytokines; Down-Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lymphocytes; Oligonucleotide Array Sequence Analysis; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2011 |
Study of Atorvastatin in experimental allergic airway inflammation in mice.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Cholesterol; Cytokines; Dexamethasone; Drug Interactions; Heptanoic Acids; Immunoglobulin E; Inflammation; Leukocytes; Male; Mice; Ovalbumin; Pyrroles; Respiratory System | 2011 |
Statins exert differential effects on angiotensin II-induced atherosclerosis, but no benefit for abdominal aortic aneurysms.
Topics: Angiotensin II; Animal Feed; Animals; Anti-Inflammatory Agents; Aorta; Aortic Aneurysm, Abdominal; Apolipoproteins E; Atherosclerosis; Atorvastatin; Blood Pressure; Fluorobenzenes; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Mice; Mice, Inbred C57BL; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2011 |
Suppression of inflammatory response and endothelial nitric oxide synthase downregulation in hyperlipidaemic C57BL/6J mice by eugenosedin-A.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Atorvastatin; Dietary Fats; Down-Regulation; Endothelium, Vascular; Female; Heptanoic Acids; Hyperlipidemias; Inflammation; Interferon-gamma; Liver; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Nitric Oxide; Nitric Oxide Synthase Type III; Obesity; Piperazines; Pyrroles; Random Allocation; RNA, Messenger; Tumor Necrosis Factor-alpha | 2011 |
Atorvastatin suppresses inflammatory response induced by oxLDL through inhibition of ERK phosphorylation, IκBα degradation, and COX-2 expression in murine macrophages.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Cell Line; Cell Shape; Chemokines; Cyclooxygenase 2; Gene Expression; Gene Expression Regulation, Enzymologic; Heptanoic Acids; I-kappa B Proteins; Inflammation; Lipoproteins, LDL; Macrophages; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; NF-KappaB Inhibitor alpha; Phosphorylation; Protein Processing, Post-Translational; Proteolysis; Pyrroles | 2012 |
Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acute Coronary Syndrome; Aged; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Lipoproteins; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Ischemia; Oxidation-Reduction; Phospholipases A2, Secretory; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk; Risk Factors; Survival Analysis | 2012 |
Nitric oxide enhances the anti-inflammatory and anti-atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Disease Models, Animal; Heptanoic Acids; Inflammation; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide; Pyrroles; Receptors, LDL | 2012 |
Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-KrasG12D-LSL-Trp53R172H-Pdx1-Cre mice.
Topics: Animals; Atorvastatin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Epoxide Hydrolases; Heptanoic Acids; Homeodomain Proteins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Ki-67 Antigen; Mice; Pancreas; Pancreatic Neoplasms; Phosphorylation; Prenylation; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins p21(ras); Pyrroles; Trans-Activators; Transcriptome; Tumor Suppressor Protein p53 | 2013 |
Synergistic inhibition of interleukin-6 production in adipose stem cells by tart cherry anthocyanins and atorvastatin.
Topics: Adipose Tissue; Anthocyanins; Anti-Inflammatory Agents; Atorvastatin; Cells, Cultured; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Fruit; Glucosides; Heptanoic Acids; Herb-Drug Interactions; Humans; Inflammation; Interleukin-6; Lipopolysaccharides; Phytotherapy; Plant Extracts; Prunus; Pyrroles; Stem Cells | 2012 |
Atorvastatin and pitavastatin reduce senile plaques and inflammatory responses in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Atorvastatin; Brain; Disease Models, Animal; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Inflammation; Mice; Mice, Transgenic; Plaque, Amyloid; Pyrroles; Quinolines | 2012 |
Atorvastatin preconditioning improves the forward blood flow in the no-reflow rats.
Topics: Animals; Atorvastatin; Echocardiography; Fibrinogen; Fibrosis; Hemodynamics; Heptanoic Acids; Inflammation; Male; Microcirculation; Myocardial Reperfusion Injury; Myocardium; Myocytes, Cardiac; Pyrroles; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Tumor Necrosis Factor-alpha | 2014 |
Effects of statins on oxidative stress and primed polymorphonuclear leukocytes in hyperlipidemic patients.
Topics: Adult; Apoptosis; Atorvastatin; Biomarkers; CD11b Antigen; Cells, Cultured; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Inflammation; Leukocyte Count; Male; Neutrophils; Oxidative Stress; Phorbol Esters; Pyrroles; Superoxides | 2012 |
Surface engineering of titanium substrates with chitosan-atorvastatin conjugate for reduced inflammation responses and improved cytocompatibility.
Topics: Acid Phosphatase; Animals; Atorvastatin; Biocompatible Materials; Cells, Immobilized; Chitosan; Cytokines; Dogs; Fluorescent Antibody Technique; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; L-Lactate Dehydrogenase; Macrophages; Magnetic Resonance Spectroscopy; Microscopy, Electron, Scanning; Nitric Oxide; Proteins; Pyrroles; Reactive Oxygen Species; Surface Properties; Titanium | 2013 |
Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice.
Topics: Animals; Atherosclerosis; Atorvastatin; Biomarkers; Cholesterol, Dietary; Cholesterol, LDL; Drug Synergism; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mice; Mice, Transgenic; Oxidative Stress; Pyrroles; Resveratrol; Stilbenes | 2013 |
The effect of atorvastatin and simvastatin on vitamin D, oxidative stress and inflammatory marker concentrations in patients with type 2 diabetes: a crossover study.
Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Pyrroles; Simvastatin; Treatment Outcome; Vitamin D | 2013 |
The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells.
Topics: Atorvastatin; Blood Coagulation; Cells, Cultured; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Oligonucleotide Array Sequence Analysis; Pyrroles; Quinolines; Receptors, LDL; RNA, Messenger; Vasoconstriction | 2002 |
HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells.
Topics: Atorvastatin; Cell Line; Cell Survival; Down-Regulation; Endothelial Growth Factors; Endothelium, Vascular; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoxia-Inducible Factor 1, alpha Subunit; I-kappa B Proteins; Inflammation; Lovastatin; Muscle, Smooth, Vascular; NF-kappa B; NF-KappaB Inhibitor alpha; Plasminogen Activator Inhibitor 1; Protein Binding; Proto-Oncogene Proteins c-jun; Pyrroles; RNA, Messenger; Simvastatin; Transcription Factor AP-1; Transcription Factors; Vascular Endothelial Growth Factor A | 2003 |
Atorvastatin limits the pro-inflammatory response of rat aortic smooth muscle cells to thrombin.
Topics: Animals; Aorta, Thoracic; Atorvastatin; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Inflammation; Male; Mice; Muscle, Smooth, Vascular; Pyrroles; Rats; Rats, Wistar; Thrombin | 2003 |
C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Topics: Acute-Phase Reaction; Aspirin; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Artery Disease; Heptanoic Acids; Humans; Incidence; Inflammation; Interleukin-6; Lovastatin; Pravastatin; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin | 2004 |
Statins inhibit in vitro calcification of human vascular smooth muscle cells induced by inflammatory mediators.
Topics: Alkaline Phosphatase; Atorvastatin; Calcinosis; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mevalonic Acid; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Polyisoprenyl Phosphates; Pyridines; Pyrroles; Sesquiterpenes | 2004 |
[Endothelial dysfunction, inflammation and statins: new evidences].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Coronary Circulation; Endothelium, Vascular; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Interleukin-6; Pravastatin; Pyrroles; Rabbits; Time Factors | 2004 |
Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice.
Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoprotein E3; Apolipoproteins E; Arteriosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol; Diet; Diet, Atherogenic; Drug Administration Schedule; Female; Heptanoic Acids; Inflammation; Male; Mice; Mice, Transgenic; Pyrroles; Serum Amyloid A Protein | 2005 |
Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of hemostasis, inflammation and apoptosis.
Topics: Adult; Anticholesteremic Agents; Apoptosis; Atorvastatin; Cholesterol; Cluster Analysis; Gene Expression Regulation; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Leukocytes; Leukocytes, Mononuclear; Lipid Metabolism; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Pyrroles; Receptors, LDL; Reverse Transcriptase Polymerase Chain Reaction; RNA; Time Factors | 2005 |
Effects of atorvastatin on inflammation and oxidative stress.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Insulin Resistance; Isoprostanes; Middle Aged; Oxidative Stress; Pyrroles; Tunica Intima | 2005 |
99mTc-interleukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Diet, Atherogenic; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-2; Male; Middle Aged; Pyrroles; Radionuclide Imaging; Technetium | 2006 |
Effect of statin therapy on serum trace element status in dyslipidaemic subjects.
Topics: Adult; Antioxidants; Atorvastatin; Blood Chemical Analysis; Ceruloplasmin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Trace Elements | 2005 |
Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism.
Topics: Antioxidants; Apoptosis; Atherosclerosis; Atorvastatin; Cell Membrane; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Lipid Peroxidation; Membrane Lipids; Models, Biological; Oxidative Stress; Pyrroles; X-Ray Diffraction | 2006 |
Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes.
Topics: Amino Acid Chloromethyl Ketones; Antibodies; Atorvastatin; Caspase 1; CD28 Antigens; CD3 Complex; Cells, Cultured; Enzyme Activation; Heptanoic Acids; Humans; Inflammation; Interferon-gamma; Interleukin-1; Interleukin-12; Interleukin-18; Mevalonic Acid; Mitosis; Monocytes; Pyrroles; Simvastatin; Solubility; T-Lymphocytes | 2006 |
Atorvastatin and glatiramer acetate: new hope in MS?
Topics: Adjuvants, Immunologic; Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Disease Models, Animal; Drug Therapy, Combination; Glatiramer Acetate; Heptanoic Acids; Humans; Immunotherapy; Inflammation; Multiple Sclerosis; Peptides; Pyrroles | 2006 |
Effects of preoperative statin therapy on cytokines after cardiac surgery.
Topics: Aged; Anti-Inflammatory Agents; Atorvastatin; Cardiopulmonary Bypass; Coronary Artery Bypass; Female; Heart Arrest, Induced; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-10; Interleukin-6; Male; Postoperative Complications; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors | 2006 |
Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Atherosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Cytokines; Dose-Response Relationship, Drug; Endarterectomy, Carotid; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Inflammation; Macrophages; Peptide Hydrolases; Phenotype; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin | 2006 |
Atorvastatin inhibits inflammatory hypernociception.
Topics: Animals; Atorvastatin; Bradykinin; Cholesterol; Cytokines; Dinoprostone; Enzyme Inhibitors; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperalgesia; Inflammation; Interleukin-1; Lipopolysaccharides; Male; Mice; Nitric Oxide Synthase; Pain Measurement; Pyrroles; Skin | 2006 |
Tubulointerstitial macrophage accumulation is regulated by sequentially expressed osteopontin and macrophage colony-stimulating factor: implication for the role of atorvastatin.
Topics: Animals; Atorvastatin; Cell Proliferation; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Inflammation; Kidney Tubules; Lipids; Macrophage Colony-Stimulating Factor; Macrophages; Osteopontin; Pyrroles; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
The anti-atherosclerotic effects of lipid lowering with atorvastatin in patients with hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipids; Male; Middle Aged; Pyrroles; Time Factors; Tunica Intima; Tunica Media | 2006 |
The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol.
Topics: Acute Disease; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Inflammation; Male; Middle Aged; Myocardial Infarction; Prognosis; Pyrroles; Serum Amyloid A Protein; Statistics as Topic; Syndrome; Treatment Outcome; Triglycerides | 2006 |
Effect of clopidogrel on the inflammatory progression of early atherosclerosis in rabbits model.
Topics: Animals; Aspirin; Atherosclerosis; Atorvastatin; Chemokine CCL2; Clopidogrel; Diet, Atherogenic; Disease Models, Animal; Femoral Artery; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Intercellular Adhesion Molecule-1; Male; P-Selectin; Platelet Aggregation Inhibitors; Pyrroles; Rabbits; Ticlopidine; Vascular Cell Adhesion Molecule-1 | 2007 |
Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Collagen; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Heart; Heptanoic Acids; Inflammation; Myocardium; Pyrroles; Rats; Rats, Sprague-Dawley; Ventricular Dysfunction, Left; Ventricular Function, Left | 2007 |
Low-dose treatment with atorvastatin leads to anti-oxidative and anti-inflammatory effects in diabetes mellitus.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Antioxidants; Atorvastatin; Diabetes Mellitus, Experimental; Endothelium, Vascular; Gene Expression; Heptanoic Acids; Inflammation; Inflammation Mediators; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; NADPH Oxidases; Oxidative Stress; Phosphorylation; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Streptozocin; Transcription Factor RelA; Vasodilation | 2007 |
E-selectin and TFPI are associated with carotid intima-media thickness in stable IHD patients: the baseline findings of the MIAMI study.
Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Artery Diseases; Cholesterol; E-Selectin; Endothelium, Vascular; Female; Fibrinogen; Heptanoic Acids; Humans; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-6; Interleukin-8; Lipoproteins; Male; Middle Aged; Prospective Studies; Pyrroles; Thromboplastin; Triglycerides; Tumor Necrosis Factor-alpha; Tunica Intima; Vascular Cell Adhesion Molecule-1; von Willebrand Factor | 2008 |
A pivotal role for interleukin-4 in atorvastatin-associated neuroprotection in rat brain.
Topics: Animals; Atorvastatin; Brain Chemistry; Cholesterol; Gene Expression Regulation; Heptanoic Acids; Hippocampus; Histocompatibility Antigens Class II; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interferon-gamma; Interleukin-1beta; Interleukin-4; Lipopolysaccharides; Male; Mice; Mice, Knockout; Microglia; Neuroprotective Agents; Pyrroles; Rats; Rats, Wistar | 2008 |
Monocyte chemoattractant protein-1 expression is enhanced by granulocyte-macrophage colony-stimulating factor via Jak2-Stat5 signaling and inhibited by atorvastatin in human monocytic U937 cells.
Topics: Atorvastatin; Chemokine CCL2; Down-Regulation; Granulocyte-Macrophage Colony-Stimulating Factor; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Janus Kinase 2; Monocytes; Pyrroles; Response Elements; RNA Stability; RNA, Messenger; Signal Transduction; STAT5 Transcription Factor; Transcription, Genetic; U937 Cells; Up-Regulation | 2008 |
Anti-inflammatory effects of combined treatment with acetyl salicylic acid and atorvastatin in haemodialysis patients affected by Normal Weight Obese syndrome.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Atorvastatin; Body Fat Distribution; Body Mass Index; Body Weight; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Inflammation; Kidney Failure, Chronic; Lipid Metabolism; Male; Middle Aged; Nutrition Assessment; Obesity; Prealbumin; Pyrroles; Renal Dialysis; Serum Albumin; Syndrome | 2008 |
Pleiotropic effects of atorvastatin in heart failure: role in oxidative stress, inflammation, endothelial function, and exercise capacity.
Topics: Aged; Atorvastatin; Biomarkers; Brachial Artery; Chronic Disease; Endothelium, Vascular; Exercise Tolerance; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Time Factors; Vasodilation; Walking | 2008 |
Biphasic effects of atorvastatin on inflammation.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Carrageenan; Edema; Heptanoic Acids; Hindlimb; Inflammation; Male; Mevalonic Acid; Mice; Pyrroles; Rats; Rats, Wistar | 2008 |
Treating residual cardiovascular risk: will lipoprotein-associated phospholipase A2 inhibition live up to its promise?
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Inflammation; Pyrroles | 2008 |
Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin.
Topics: Animals; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Drug Synergism; Heptanoic Acids; Inflammation; Mice; Mice, Inbred Strains; Pyrroles; Quinolines | 2008 |
Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration.
Topics: Animals; Anticholesteremic Agents; Aortic Aneurysm, Abdominal; Atorvastatin; Cell Movement; Collagen; Disease Models, Animal; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Macrophages; Pancreatic Elastase; Pyrroles; Rats; Rats, Wistar; Treatment Outcome | 2009 |
Short term effects of atorvastatin on endothelial functions and oxidized LDL levels in patients with type 2 diabetes.
Topics: Atherosclerosis; Atorvastatin; Biomarkers; Brachial Artery; Carotid Arteries; Cholesterol, LDL; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Inflammation; Lipids; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Tunica Intima | 2008 |
HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.
Topics: Animals; Atorvastatin; Chemokine CCL2; Coronary Artery Disease; Disease Models, Animal; Evaluation Studies as Topic; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; NF-kappa B; Pyrroles; Rabbits; Random Allocation; Tunica Intima | 1998 |
Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells.
Topics: Animals; Atorvastatin; Base Sequence; Blotting, Western; Cells, Cultured; Chemokines; Coronary Artery Disease; Coronary Vessels; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Molecular Sequence Data; Monocytes; Muscle, Smooth, Vascular; NF-kappa B; Polymerase Chain Reaction; Pyrroles; Rats; Reproducibility of Results; Sensitivity and Specificity | 1999 |
The state of the heart. If you thought cholesterol was all you had to worry about, better think again.
Topics: American Heart Association; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Folic Acid; Heptanoic Acids; Humans; Inflammation; Pyrroles; United States | 2000 |
Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes.
Topics: Anticholesteremic Agents; Atorvastatin; Cell Death; Cells, Cultured; Chemokine CCL2; Heptanoic Acids; Humans; Inflammation; Matrix Metalloproteinase 9; Monocytes; Oxygen Consumption; Pyrroles; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Tumor Necrosis Factor-alpha | 2002 |